Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular...
Saved in:
| Published in | The Lancet (British edition) Vol. 366; no. 9500; pp. 1849 - 1861 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
26.11.2005
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0140-6736 1474-547X 1474-547X |
| DOI | 10.1016/S0140-6736(05)67667-2 |
Cover
| Abstract | Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients.
We did a multinational, randomised controlled trial with 9795 participants aged 50–75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned patients (2131 with previous cardiovascular disease and 7664 without) with a total-cholesterol concentration of 3·0–6·5 mmol/L and a total-cholesterol/HDL-cholesterol ratio of 4·0 or more or plasma triglyceride of 1·0–5·0 mmol/L to micronised fenofibrate 200 mg daily (n=4895) or matching placebo (n=4900). Our primary outcome was coronary events (coronary heart disease death or non-fatal myocardial infarction); the outcome for prespecified subgroup analyses was total cardiovascular events (the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularisation). Analysis was by intention to treat. The study was prospectively registered (number ISRCTN 64783481).
Vital status was confirmed on all but 22 patients. Averaged over the 5 years' study duration, similar proportions in each group discontinued study medication (10% placebo
vs 11% fenofibrate) and more patients allocated placebo (17%) than fenofibrate (8%; p<0·0001) commenced other lipid treatments, predominantly statins. 5·9% (n=288) of patients on placebo and 5·2% (n=256) of those on fenofibrate had a coronary event (relative reduction of 11%; hazard ratio [HR] 0·89, 95% CI 0·75–1·05; p=0·16). This finding corresponds to a significant 24% reduction in non-fatal myocardial infarction (0·76, 0·62–0·94; p=0·010) and a non-significant increase in coronary heart disease mortality (1·19, 0·90–1·57; p=0·22). Total cardiovascular disease events were significantly reduced from 13·9% to 12·5% (0·89, 0·80–0·99; p=0·035). This finding included a 21% reduction in coronary revascularisation (0·79, 0·68–0·93; p=0·003). Total mortality was 6·6% in the placebo group and 7·3% in the fenofibrate group (p=0·18). Fenofibrate was associated with less albuminuria progression (p=0·002), and less retinopathy needing laser treatment (5·2%
vs 3·6%, p=0·0003). There was a slight increase in pancreatitis (0·5%
vs 0·8%, p=0·031) and pulmonary embolism (0·7%
vs 1·1%, p=0·022), but no other significant adverse effects.
Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events. It did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. The higher rate of starting statin therapy in patients allocated placebo might have masked a moderately larger treatment benefit. |
|---|---|
| AbstractList | Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients.
We did a multinational, randomised controlled trial with 9795 participants aged 50–75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned patients (2131 with previous cardiovascular disease and 7664 without) with a total-cholesterol concentration of 3·0–6·5 mmol/L and a total-cholesterol/HDL-cholesterol ratio of 4·0 or more or plasma triglyceride of 1·0–5·0 mmol/L to micronised fenofibrate 200 mg daily (n=4895) or matching placebo (n=4900). Our primary outcome was coronary events (coronary heart disease death or non-fatal myocardial infarction); the outcome for prespecified subgroup analyses was total cardiovascular events (the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularisation). Analysis was by intention to treat. The study was prospectively registered (number ISRCTN 64783481).
Vital status was confirmed on all but 22 patients. Averaged over the 5 years' study duration, similar proportions in each group discontinued study medication (10% placebo
vs 11% fenofibrate) and more patients allocated placebo (17%) than fenofibrate (8%; p<0·0001) commenced other lipid treatments, predominantly statins. 5·9% (n=288) of patients on placebo and 5·2% (n=256) of those on fenofibrate had a coronary event (relative reduction of 11%; hazard ratio [HR] 0·89, 95% CI 0·75–1·05; p=0·16). This finding corresponds to a significant 24% reduction in non-fatal myocardial infarction (0·76, 0·62–0·94; p=0·010) and a non-significant increase in coronary heart disease mortality (1·19, 0·90–1·57; p=0·22). Total cardiovascular disease events were significantly reduced from 13·9% to 12·5% (0·89, 0·80–0·99; p=0·035). This finding included a 21% reduction in coronary revascularisation (0·79, 0·68–0·93; p=0·003). Total mortality was 6·6% in the placebo group and 7·3% in the fenofibrate group (p=0·18). Fenofibrate was associated with less albuminuria progression (p=0·002), and less retinopathy needing laser treatment (5·2%
vs 3·6%, p=0·0003). There was a slight increase in pancreatitis (0·5%
vs 0·8%, p=0·031) and pulmonary embolism (0·7%
vs 1·1%, p=0·022), but no other significant adverse effects.
Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events. It did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. The higher rate of starting statin therapy in patients allocated placebo might have masked a moderately larger treatment benefit. Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients. We did a multinational, randomised controlled trial with 9795 participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned patients (2131 with previous cardiovascular disease and 7664 without) with a total-cholesterol concentration of 3.0-6.5 mmol/L and a total-cholesterol/HDL-cholesterol ratio of 4.0 or more or plasma triglyceride of 1.0-5.0 mmol/L to micronised fenofibrate 200 mg daily (n=4895) or matching placebo (n=4900). Our primary outcome was coronary events (coronary heart disease death or non-fatal myocardial infarction); the outcome for prespecified subgroup analyses was total cardiovascular events (the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularisation). Analysis was by intention to treat. The study was prospectively registered (number ISRCTN 64783481). Vital status was confirmed on all but 22 patients. Averaged over the 5 years' study duration, similar proportions in each group discontinued study medication (10% placebo vs 11% fenofibrate) and more patients allocated placebo (17%) than fenofibrate (8%; p<0.0001) commenced other lipid treatments, predominantly statins. 5.9% (n=288) of patients on placebo and 5.2% (n=256) of those on fenofibrate had a coronary event (relative reduction of 11%; hazard ratio [HR] 0.89, 95% CI 0.75-1.05; p=0.16). This finding corresponds to a significant 24% reduction in non-fatal myocardial infarction (0.76, 0.62-0.94; p=0.010) and a non-significant increase in coronary heart disease mortality (1.19, 0.90-1.57; p=0.22). Total cardiovascular disease events were significantly reduced from 13.9% to 12.5% (0.89, 0.80-0.99; p=0.035). This finding included a 21% reduction in coronary revascularisation (0.79, 0.68-0.93; p=0.003). Total mortality was 6.6% in the placebo group and 7.3% in the fenofibrate group (p=0.18). Fenofibrate was associated with less albuminuria progression (p=0.002), and less retinopathy needing laser treatment (5.2%vs 3.6%, p=0.0003). There was a slight increase in pancreatitis (0.5%vs 0.8%, p=0.031) and pulmonary embolism (0.7%vs 1.1%, p=0.022), but no other significant adverse effects. Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events. It did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. The higher rate of starting statin therapy in patients allocated placebo might have masked a moderately larger treatment benefit. Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients. We did a multinational, randomised controlled trial with 9795 participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned patients (2131 with previous cardiovascular disease and 7664 without) with a total-cholesterol concentration of 3.0-6.5 mmol/L and a total-cholesterol/HDL-cholesterol ratio of 4.0 or more or plasma triglyceride of 1.0-5.0 mmol/L to micronised fenofibrate 200 mg daily (n=4895) or matching placebo (n=4900). Our primary outcome was coronary events (coronary heart disease death or non-fatal myocardial infarction); the outcome for prespecified subgroup analyses was total cardiovascular events (the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularisation). Analysis was by intention to treat. The study was prospectively registered (number ISRCTN 64783481). Vital status was confirmed on all but 22 patients. Averaged over the 5 years' study duration, similar proportions in each group discontinued study medication (10% placebo vs 11% fenofibrate) and more patients allocated placebo (17%) than fenofibrate (8%; p<0.0001) commenced other lipid treatments, predominantly statins. 5.9% (n=288) of patients on placebo and 5.2% (n=256) of those on fenofibrate had a coronary event (relative reduction of 11%; hazard ratio [HR] 0.89, 95% CI 0.75-1.05; p=0.16). This finding corresponds to a significant 24% reduction in non-fatal myocardial infarction (0.76, 0.62-0.94; p=0.010) and a non-significant increase in coronary heart disease mortality (1.19, 0.90-1.57; p=0.22). Total cardiovascular disease events were significantly reduced from 13.9% to 12.5% (0.89, 0.80-0.99; p=0.035). This finding included a 21% reduction in coronary revascularisation (0.79, 0.68-0.93; p=0.003). Total mortality was 6.6% in the placebo group and 7.3% in the fenofibrate group (p=0.18). Fenofibrate was associated with less albuminuria progression (p=0.002), and less retinopathy needing laser treatment (5.2%vs 3.6%, p=0.0003). There was a slight increase in pancreatitis (0.5%vs 0.8%, p=0.031) and pulmonary embolism (0.7%vs 1.1%, p=0.022), but no other significant adverse effects. Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events. It did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. The higher rate of starting statin therapy in patients allocated placebo might have masked a moderately larger treatment benefit. Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients.BACKGROUNDPatients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients.We did a multinational, randomised controlled trial with 9795 participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned patients (2131 with previous cardiovascular disease and 7664 without) with a total-cholesterol concentration of 3.0-6.5 mmol/L and a total-cholesterol/HDL-cholesterol ratio of 4.0 or more or plasma triglyceride of 1.0-5.0 mmol/L to micronised fenofibrate 200 mg daily (n=4895) or matching placebo (n=4900). Our primary outcome was coronary events (coronary heart disease death or non-fatal myocardial infarction); the outcome for prespecified subgroup analyses was total cardiovascular events (the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularisation). Analysis was by intention to treat. The study was prospectively registered (number ISRCTN 64783481).METHODSWe did a multinational, randomised controlled trial with 9795 participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned patients (2131 with previous cardiovascular disease and 7664 without) with a total-cholesterol concentration of 3.0-6.5 mmol/L and a total-cholesterol/HDL-cholesterol ratio of 4.0 or more or plasma triglyceride of 1.0-5.0 mmol/L to micronised fenofibrate 200 mg daily (n=4895) or matching placebo (n=4900). Our primary outcome was coronary events (coronary heart disease death or non-fatal myocardial infarction); the outcome for prespecified subgroup analyses was total cardiovascular events (the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularisation). Analysis was by intention to treat. The study was prospectively registered (number ISRCTN 64783481).Vital status was confirmed on all but 22 patients. Averaged over the 5 years' study duration, similar proportions in each group discontinued study medication (10% placebo vs 11% fenofibrate) and more patients allocated placebo (17%) than fenofibrate (8%; p<0.0001) commenced other lipid treatments, predominantly statins. 5.9% (n=288) of patients on placebo and 5.2% (n=256) of those on fenofibrate had a coronary event (relative reduction of 11%; hazard ratio [HR] 0.89, 95% CI 0.75-1.05; p=0.16). This finding corresponds to a significant 24% reduction in non-fatal myocardial infarction (0.76, 0.62-0.94; p=0.010) and a non-significant increase in coronary heart disease mortality (1.19, 0.90-1.57; p=0.22). Total cardiovascular disease events were significantly reduced from 13.9% to 12.5% (0.89, 0.80-0.99; p=0.035). This finding included a 21% reduction in coronary revascularisation (0.79, 0.68-0.93; p=0.003). Total mortality was 6.6% in the placebo group and 7.3% in the fenofibrate group (p=0.18). Fenofibrate was associated with less albuminuria progression (p=0.002), and less retinopathy needing laser treatment (5.2%vs 3.6%, p=0.0003). There was a slight increase in pancreatitis (0.5%vs 0.8%, p=0.031) and pulmonary embolism (0.7%vs 1.1%, p=0.022), but no other significant adverse effects.FINDINGSVital status was confirmed on all but 22 patients. Averaged over the 5 years' study duration, similar proportions in each group discontinued study medication (10% placebo vs 11% fenofibrate) and more patients allocated placebo (17%) than fenofibrate (8%; p<0.0001) commenced other lipid treatments, predominantly statins. 5.9% (n=288) of patients on placebo and 5.2% (n=256) of those on fenofibrate had a coronary event (relative reduction of 11%; hazard ratio [HR] 0.89, 95% CI 0.75-1.05; p=0.16). This finding corresponds to a significant 24% reduction in non-fatal myocardial infarction (0.76, 0.62-0.94; p=0.010) and a non-significant increase in coronary heart disease mortality (1.19, 0.90-1.57; p=0.22). Total cardiovascular disease events were significantly reduced from 13.9% to 12.5% (0.89, 0.80-0.99; p=0.035). This finding included a 21% reduction in coronary revascularisation (0.79, 0.68-0.93; p=0.003). Total mortality was 6.6% in the placebo group and 7.3% in the fenofibrate group (p=0.18). Fenofibrate was associated with less albuminuria progression (p=0.002), and less retinopathy needing laser treatment (5.2%vs 3.6%, p=0.0003). There was a slight increase in pancreatitis (0.5%vs 0.8%, p=0.031) and pulmonary embolism (0.7%vs 1.1%, p=0.022), but no other significant adverse effects.Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events. It did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. The higher rate of starting statin therapy in patients allocated placebo might have masked a moderately larger treatment benefit.INTERPRETATIONFenofibrate did not significantly reduce the risk of the primary outcome of coronary events. It did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. The higher rate of starting statin therapy in patients allocated placebo might have masked a moderately larger treatment benefit. |
| Author | Laakso, M Glasziou, P Kesäniemi, Y A Whiting, M Simes, R J Best, J d'Emden, M Taskinen, M R Scott, R Forder, P Ehnholm, C Colman, P Drury, P Hunt, D Keech, A Davis, T Barter, P Sullivan, D Pillai, A |
| Author_xml | – sequence: 1 givenname: A surname: Keech fullname: Keech, A – sequence: 2 givenname: R J surname: Simes fullname: Simes, R J – sequence: 3 givenname: P surname: Barter fullname: Barter, P – sequence: 4 givenname: J surname: Best fullname: Best, J – sequence: 5 givenname: R surname: Scott fullname: Scott, R – sequence: 6 givenname: M R surname: Taskinen fullname: Taskinen, M R – sequence: 7 givenname: P surname: Forder fullname: Forder, P – sequence: 8 givenname: A surname: Pillai fullname: Pillai, A – sequence: 9 givenname: T surname: Davis fullname: Davis, T – sequence: 10 givenname: P surname: Glasziou fullname: Glasziou, P – sequence: 11 givenname: P surname: Drury fullname: Drury, P – sequence: 12 givenname: Y A surname: Kesäniemi fullname: Kesäniemi, Y A – sequence: 13 givenname: D surname: Sullivan fullname: Sullivan, D – sequence: 14 givenname: D surname: Hunt fullname: Hunt, D – sequence: 15 givenname: P surname: Colman fullname: Colman, P – sequence: 16 givenname: M surname: d'Emden fullname: d'Emden, M – sequence: 17 givenname: M surname: Whiting fullname: Whiting, M – sequence: 18 givenname: C surname: Ehnholm fullname: Ehnholm, C – sequence: 19 givenname: M surname: Laakso fullname: Laakso, M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16310551$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks9u1DAYxCNURP_AI4AsDqg9BOwkthMQQqhsodJKHACJm-XYn6mL1w62s2gfhnfF2y0g7aWc7MNvRqOZ77g68MFDVT0m-DnBhL34hEmHa8ZbdorpGeOM8bq5Vx2Rjnc17fjXg-roL3JYHad0jTHuGKYPqkPCWoIpJUfVr4UxoHJCwSAX_Lc6Q1whAz4YO0aZAeUriHLaoOCRklHbsJZJzU5GBGvwRWk9GvhA0QRhcoB-2nyF8mYC1CBt5QgZElqBczbPCZ0WO3RxuVi-QynPenP2EkXpdVjZBBqp4HMMzpVvjla6h9V9I12CR7fvSfXlYvH5_EO9_Pj-8vztslZd1-WaGTDtONKm5T0xGvcwtp00VJGm0UOrDce076lUnI9tP-pedqTBw0g45mAIbk-qZzvfKYYfM6QsSh5VMksPYU6C9X3bND0t4NM98DrM0ZdsggwDblnPttCTW2geV6DFFO1Kxo3403oB6A5QMaQUwfxDsNiuK27WFdvpBKbiZl3RFN2rPZ2yWWa7bU1ad6f6zU4Npcm1hSiSsuAVaBvLCQgd7J0Or_cclLPeKum-w-Y_9L8B5wXSFQ |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1007_s11886_019_1246_1 crossref_primary_10_1111_eci_12068 crossref_primary_10_1016_j_acvd_2008_09_002 crossref_primary_10_1021_acs_jmedchem_8b00835 crossref_primary_10_1016_S0304_5412_12_70426_2 crossref_primary_10_3904_kjm_2014_86_6_698 crossref_primary_10_1080_14656566_2016_1195811 crossref_primary_10_1016_j_crvasa_2014_01_003 crossref_primary_10_1007_s11033_012_2325_1 crossref_primary_10_1097_FJC_0b013e318165e2e7 crossref_primary_10_1067_j_cpsurg_2014_01_002 crossref_primary_10_1038_nrendo_2016_69 crossref_primary_10_1016_j_ahj_2008_05_017 crossref_primary_10_2337_dc18_S009 crossref_primary_10_1177_10742484211023632 crossref_primary_10_1155_2012_174932 crossref_primary_10_1007_s00044_014_1215_6 crossref_primary_10_3390_diabetology4040048 crossref_primary_10_1016_j_ijcard_2013_01_223 crossref_primary_10_1161_01_ATV_0000204327_96431_9a crossref_primary_10_2337_dc08_zb06 crossref_primary_10_1007_s11886_022_01751_z crossref_primary_10_1016_S0140_6736_06_68499_7 crossref_primary_10_1186_s13063_022_06031_3 crossref_primary_10_1155_2008_328172 crossref_primary_10_1161_CIRCRESAHA_110_226860 crossref_primary_10_1111_j_1464_5491_2007_02186_x crossref_primary_10_2337_dc08_zb11 crossref_primary_10_1016_j_cca_2009_11_026 crossref_primary_10_1586_14779072_6_3_323 crossref_primary_10_1038_nrcardio_2011_2 crossref_primary_10_1373_clinchem_2007_097907 crossref_primary_10_2217_clp_14_62 crossref_primary_10_2165_00129784_200707040_00004 crossref_primary_10_1007_s11154_020_09575_4 crossref_primary_10_1016_j_ijcard_2015_04_228 crossref_primary_10_1016_j_jdiacomp_2008_01_004 crossref_primary_10_1016_j_numecd_2012_05_005 crossref_primary_10_1177_14746514060060020401 crossref_primary_10_1016_S0828_282X_08_71035_3 crossref_primary_10_3390_metabo11050330 crossref_primary_10_1258_acb_2007_007177 crossref_primary_10_2337_dc14_0180 crossref_primary_10_1111_eci_14227 crossref_primary_10_1016_j_mayocpiqo_2023_04_010 crossref_primary_10_1016_j_trsl_2023_11_002 crossref_primary_10_1016_S0304_5412_12_70448_1 crossref_primary_10_1016_j_ijge_2017_07_001 crossref_primary_10_1016_j_metabol_2007_08_009 crossref_primary_10_1007_s00380_018_1173_x crossref_primary_10_1016_j_brainres_2009_04_055 crossref_primary_10_1111_eci_14214 crossref_primary_10_12998_wjcc_v9_i30_9295 crossref_primary_10_1161_CIRCULATIONAHA_105_593855 crossref_primary_10_2217_clp_14_38 crossref_primary_10_1111_j_1464_5491_2006_01837_x crossref_primary_10_1016_S0001_4079_19_33007_9 crossref_primary_10_1517_17425250902785172 crossref_primary_10_1161_STR_0b013e3181fcb238 crossref_primary_10_1111_dme_12972 crossref_primary_10_1536_ihj_51_199 crossref_primary_10_1186_s12933_016_0332_6 crossref_primary_10_1038_ncpcardio1278 crossref_primary_10_1002_pdi_1474 crossref_primary_10_2337_dc12_1801 crossref_primary_10_1097_MOL_0b013e32832210b0 crossref_primary_10_1016_j_atherosclerosis_2006_07_010 crossref_primary_10_1111_j_1463_1326_2006_00594_x crossref_primary_10_1007_s10557_010_6245_9 crossref_primary_10_1016_j_amjcard_2012_07_007 crossref_primary_10_1016_j_arteri_2013_03_001 crossref_primary_10_1007_s00592_013_0542_2 crossref_primary_10_1016_j_biopha_2023_116092 crossref_primary_10_1016_j_atherosclerosis_2014_09_026 crossref_primary_10_1016_j_semnephrol_2018_02_003 crossref_primary_10_1161_JAHA_118_008953 crossref_primary_10_1136_bmjopen_2019_030596 crossref_primary_10_1016_j_jacl_2009_09_003 crossref_primary_10_1517_14740338_2015_1056778 crossref_primary_10_1016_j_thromres_2015_04_005 crossref_primary_10_1097_01_mol_0000245268_78752_8e crossref_primary_10_1007_s13410_016_0500_y crossref_primary_10_1016_S0214_9168_16_30083_3 crossref_primary_10_1097_MD_0000000000000619 crossref_primary_10_1371_journal_pone_0255147 crossref_primary_10_1111_ijcp_12762 crossref_primary_10_1016_j_atherosclerosis_2009_07_021 crossref_primary_10_1097_MED_0b013e3282f5ff98 crossref_primary_10_1177_1474651412470289 crossref_primary_10_1155_2012_456529 crossref_primary_10_1161_STR_0b013e3182112cc2 crossref_primary_10_1038_nrneph_2017_107 crossref_primary_10_1016_j_hfc_2012_06_012 crossref_primary_10_1016_j_phrs_2023_106873 crossref_primary_10_1007_s11883_009_0053_3 crossref_primary_10_1007_s00508_016_0993_x crossref_primary_10_1111_j_1368_5031_2006_00882_x crossref_primary_10_1007_s11883_014_0475_4 crossref_primary_10_1016_S0214_9168_06_73679_8 crossref_primary_10_1097_FJC_0b013e31823de86b crossref_primary_10_2217_clp_14_10 crossref_primary_10_1002_dmrr_806 crossref_primary_10_1007_s10557_011_6368_7 crossref_primary_10_3389_fcvm_2022_813208 crossref_primary_10_1016_j_mpmed_2014_10_011 crossref_primary_10_2478_abm_2024_0033 crossref_primary_10_1093_ehjcvp_pvy029 crossref_primary_10_1111_j_1365_2362_2006_01677_x crossref_primary_10_1586_14779072_6_3_369 crossref_primary_10_1016_j_numecd_2006_08_001 crossref_primary_10_1111_j_1742_1241_2011_02769_x crossref_primary_10_1177_2042018811419157 crossref_primary_10_1515_CCLM_2007_358 crossref_primary_10_1161_CIRCULATIONAHA_110_960112 crossref_primary_10_1016_j_cca_2019_07_005 crossref_primary_10_1002_jcla_22688 crossref_primary_10_1016_j_amjcard_2007_03_002 crossref_primary_10_1177_14746514070070010501 crossref_primary_10_1161_JAHA_118_009866 crossref_primary_10_1016_j_jacbts_2024_09_002 crossref_primary_10_2337_dc11_S011 crossref_primary_10_1056_NEJMp1106688 crossref_primary_10_1016_j_ejim_2008_06_009 crossref_primary_10_1007_s11745_007_3103_z crossref_primary_10_3389_fcvm_2018_00071 crossref_primary_10_1016_j_cjca_2012_03_017 crossref_primary_10_1016_j_jacl_2021_05_007 crossref_primary_10_1016_j_ccl_2015_02_007 crossref_primary_10_1111_j_1755_5922_2011_00307_x crossref_primary_10_1007_s11883_016_0620_3 crossref_primary_10_5937_siks1104210S crossref_primary_10_1016_j_acvd_2009_02_008 crossref_primary_10_1186_s13063_020_04374_3 crossref_primary_10_1186_s13063_016_1752_z crossref_primary_10_1038_s41573_019_0040_5 crossref_primary_10_2217_17460875_1_4_463 crossref_primary_10_1016_j_mcna_2011_06_005 crossref_primary_10_1002_cpt_798 crossref_primary_10_1111_dom_13938 crossref_primary_10_1007_s11886_011_0237_7 crossref_primary_10_1016_j_ccl_2017_12_001 crossref_primary_10_1016_j_ijdm_2010_11_001 crossref_primary_10_1097_MOL_0b013e3283613a7d crossref_primary_10_1016_j_ccl_2017_12_005 crossref_primary_10_1111_j_1755_6686_2010_00173_x crossref_primary_10_1007_s13340_018_0345_3 crossref_primary_10_1016_j_yexcr_2013_04_007 crossref_primary_10_1093_eurheartj_ehv043 crossref_primary_10_1517_17425255_2011_579561 crossref_primary_10_1177_1545109711404945 crossref_primary_10_1016_j_amjcard_2007_03_024 crossref_primary_10_1016_j_eprac_2024_08_013 crossref_primary_10_31083_j_rcm2512436 crossref_primary_10_1016_j_endonu_2016_01_001 crossref_primary_10_1016_j_jacc_2012_07_049 crossref_primary_10_31435_rsglobal_ws_30062024_8172 crossref_primary_10_2174_0115733998253672231011161400 crossref_primary_10_2337_dc10_zb11 crossref_primary_10_1161_CIRCULATIONAHA_106_179294 crossref_primary_10_1155_2010_345098 crossref_primary_10_1016_j_repc_2019_10_001 crossref_primary_10_1007_s00125_007_0698_9 crossref_primary_10_15829_1560_4071_2024_6110 crossref_primary_10_1016_j_preteyeres_2007_12_001 crossref_primary_10_2337_dc06_2558 crossref_primary_10_1016_j_diabres_2019_03_028 crossref_primary_10_1517_14656566_2011_563506 crossref_primary_10_1016_j_diabres_2012_01_017 crossref_primary_10_5551_jat_19349 crossref_primary_10_2337_dc10_zb08 crossref_primary_10_2337_dc21_1439 crossref_primary_10_1111_j_1751_7176_2011_00446_x crossref_primary_10_3810_pgm_2010_03_2119 crossref_primary_10_1093_eurheartj_ehz455 crossref_primary_10_1517_14656566_2015_1009894 crossref_primary_10_1002_pauz_200600209 crossref_primary_10_1007_s13340_015_0225_z crossref_primary_10_3810_pgm_2014_11_2831 crossref_primary_10_4239_wjd_v10_i5_280 crossref_primary_10_3747_pdi_2011_00026 crossref_primary_10_3132_dvdr_2008_002 crossref_primary_10_1186_1476_511X_11_47 crossref_primary_10_1002_lipd_12374 crossref_primary_10_1177_14746514060060030601 crossref_primary_10_1001_jamacardio_2018_2112 crossref_primary_10_1016_j_endoen_2016_05_002 crossref_primary_10_1016_j_clinthera_2009_12_007 crossref_primary_10_1007_s10735_011_9313_y crossref_primary_10_1080_20786204_2006_10873484 crossref_primary_10_1185_03007995_2010_505463 crossref_primary_10_1016_j_mcna_2011_11_006 crossref_primary_10_1185_030079907X187892 crossref_primary_10_1258_MI_2007_007037 crossref_primary_10_2337_dc09_S013 crossref_primary_10_1038_nrcardio_2009_94 crossref_primary_10_1097_MCA_0b013e32833bfdcd crossref_primary_10_2337_dcS13_2003 crossref_primary_10_3389_fendo_2023_1322869 crossref_primary_10_1177_0897190008326444 crossref_primary_10_1291_hypres_31_999 crossref_primary_10_1016_j_dsx_2008_04_001 crossref_primary_10_3390_ijms231810882 crossref_primary_10_1097_FJC_0b013e318202709f crossref_primary_10_1157_13124997 crossref_primary_10_1016_j_mpmed_2010_08_005 crossref_primary_10_1038_tpj_2010_86 crossref_primary_10_1186_s12933_020_01002_x crossref_primary_10_1007_s12170_019_0618_9 crossref_primary_10_1007_s40265_015_0429_3 crossref_primary_10_1111_j_1476_5381_2008_00109_x crossref_primary_10_1016_S1957_2557_10_70001_8 crossref_primary_10_1016_j_jacc_2021_06_011 crossref_primary_10_3389_fcvm_2022_965995 crossref_primary_10_1016_j_jhep_2019_05_016 crossref_primary_10_1097_CRD_0b013e31816b43d3 crossref_primary_10_3390_biomedicines11020561 crossref_primary_10_1016_j_ekir_2016_07_007 crossref_primary_10_1097_FJC_0000000000001153 crossref_primary_10_1111_joim_13771 crossref_primary_10_1136_bmj_l5125 crossref_primary_10_2165_11533430_000000000_00000 crossref_primary_10_1146_annurev_med_59_121206_112237 crossref_primary_10_2165_10061630_000000000_00000 crossref_primary_10_1016_j_plipres_2011_04_002 crossref_primary_10_1016_S0828_282X_09_70715_9 crossref_primary_10_1007_s12170_012_0231_7 crossref_primary_10_1016_j_endien_2022_11_009 crossref_primary_10_1016_j_numecd_2021_02_029 crossref_primary_10_2169_naika_106_711 crossref_primary_10_1161_ATVBAHA_107_144980 crossref_primary_10_1038_nrendo_2011_235 crossref_primary_10_1097_MOL_0b013e3282f0dd33 crossref_primary_10_1016_j_metabol_2017_02_013 crossref_primary_10_1016_j_amjcard_2008_02_038 crossref_primary_10_1111_j_1600_0420_2007_00944_x crossref_primary_10_1007_s00508_012_0273_3 crossref_primary_10_1016_j_atherosclerosis_2019_08_014 crossref_primary_10_1007_s11883_008_0015_1 crossref_primary_10_1530_JOE_13_0578 crossref_primary_10_1016_j_jacl_2008_10_001 crossref_primary_10_1007_s00125_008_1179_5 crossref_primary_10_1186_1755_1536_7_12 crossref_primary_10_54133_ajms_v7i2_1244 crossref_primary_10_1016_j_therap_2017_07_002 crossref_primary_10_1016_j_amjcard_2010_11_023 crossref_primary_10_1016_j_jacl_2007_02_004 crossref_primary_10_1016_j_jcjo_2017_09_027 crossref_primary_10_1007_s13300_017_0240_0 crossref_primary_10_3132_dvdr_2008_046 crossref_primary_10_5694_mja2_50142 crossref_primary_10_1007_s11892_019_1276_5 crossref_primary_10_1136_bmjopen_2018_025788 crossref_primary_10_1124_jpet_110_171090 crossref_primary_10_1016_S1957_2557_09_72387_9 crossref_primary_10_1016_j_jecm_2013_06_012 crossref_primary_10_1016_j_jmccpl_2025_100292 crossref_primary_10_1155_2016_3634948 crossref_primary_10_1016_j_jacc_2010_11_006 crossref_primary_10_1186_s12933_024_02353_5 crossref_primary_10_1016_j_jacc_2010_11_005 crossref_primary_10_1161_HYPERTENSIONAHA_108_110320 crossref_primary_10_1111_j_1365_2613_2009_00649_x crossref_primary_10_1042_CS20060072 crossref_primary_10_1161_ATVBAHA_107_160192 crossref_primary_10_2337_dcS13_2041 crossref_primary_10_1007_s11892_012_0266_7 crossref_primary_10_1016_S1957_2557_13_70531_5 crossref_primary_10_2165_11597940_000000000_00000 crossref_primary_10_3389_fphys_2020_00732 crossref_primary_10_1016_j_jacc_2008_02_034 crossref_primary_10_1517_13543784_2015_1006359 crossref_primary_10_1080_17512433_2017_1263565 crossref_primary_10_1016_j_beem_2013_11_006 crossref_primary_10_1002_emmm_201303415 crossref_primary_10_3390_nu14245378 crossref_primary_10_5551_jat_29181 crossref_primary_10_5551_jat_63081 crossref_primary_10_1161_CIRCGENETICS_112_963140 crossref_primary_10_1161_STROKEAHA_109_551416 crossref_primary_10_1016_j_cpcardiol_2007_01_004 crossref_primary_10_1016_j_endien_2025_101523 crossref_primary_10_2337_dc11_1109 crossref_primary_10_18261_ntfe_13_4_7 crossref_primary_10_1038_ncpcardio0823 crossref_primary_10_1161_CIR_0000000000000456 crossref_primary_10_1016_j_metabol_2022_155327 crossref_primary_10_1111_dom_13537 crossref_primary_10_1007_s11428_010_0605_8 crossref_primary_10_2217_14622416_10_2_267 crossref_primary_10_3390_biom11111680 crossref_primary_10_1016_j_diabres_2016_12_015 crossref_primary_10_1186_s13256_024_04532_0 crossref_primary_10_1016_j_ejmech_2024_116567 crossref_primary_10_1016_S0300_8932_07_75070_4 crossref_primary_10_1177_0003319708326452 crossref_primary_10_1007_s00108_008_2077_0 crossref_primary_10_1016_j_jacl_2010_07_007 crossref_primary_10_1016_j_amjcard_2010_11_009 crossref_primary_10_1016_j_ecl_2008_06_004 crossref_primary_10_1080_17512433_2018_1537780 crossref_primary_10_1016_j_atherosclerosis_2006_12_012 crossref_primary_10_1097_MJT_0b013e31828b8463 crossref_primary_10_1016_j_metabol_2024_155931 crossref_primary_10_1097_MOL_0000000000000465 crossref_primary_10_1007_s12181_013_0505_4 crossref_primary_10_1111_j_1365_2362_2009_02155_x crossref_primary_10_3389_fcvm_2022_982815 crossref_primary_10_2147_vhrm_2006_2_3_285 crossref_primary_10_1016_j_metabol_2023_155658 crossref_primary_10_12997_jla_2019_8_2_78 crossref_primary_10_1097_MOL_0b013e32831f1b18 crossref_primary_10_1002_chem_201805295 crossref_primary_10_1097_01_mol_0000236376_58002_90 crossref_primary_10_1155_2012_784536 crossref_primary_10_1093_eurheartj_ehp377 crossref_primary_10_1111_j_1463_1326_2012_01601_x crossref_primary_10_1111_dom_15764 crossref_primary_10_1016_S1957_2557_15_30180_2 crossref_primary_10_1016_j_gcb_2008_01_029 crossref_primary_10_1016_j_numecd_2007_05_001 crossref_primary_10_1111_j_1365_2796_2007_01825_x crossref_primary_10_1007_s11892_015_0599_0 crossref_primary_10_1016_j_jacl_2012_04_003 crossref_primary_10_1371_journal_pone_0106849 crossref_primary_10_2337_db05_1620 crossref_primary_10_1111_bcp_12945 crossref_primary_10_1210_clinem_dgae776 crossref_primary_10_1016_j_jvs_2013_06_069 crossref_primary_10_1097_MJT_0b013e318249a1b5 crossref_primary_10_1111_j_1464_5491_2008_02602_x crossref_primary_10_1016_j_atherosclerosis_2009_09_007 crossref_primary_10_1016_j_metabol_2025_156187 crossref_primary_10_1016_S0140_6736_07_61608_0 crossref_primary_10_12997_jla_2015_4_1_61 crossref_primary_10_1016_j_bmcl_2008_09_094 crossref_primary_10_1097_MEG_0b013e328321b0c8 crossref_primary_10_1016_j_arteri_2022_11_002 crossref_primary_10_3389_fcvm_2024_1389106 crossref_primary_10_1016_S0140_6736_14_61009_6 crossref_primary_10_1007_s11886_018_1051_2 crossref_primary_10_1056_NEJMoa1001282 crossref_primary_10_33678_cor_2006_025 crossref_primary_10_1093_eurheartj_ehp399 crossref_primary_10_3390_nu11071691 crossref_primary_10_1016_j_avsg_2017_09_019 crossref_primary_10_1210_jc_2008_0222 crossref_primary_10_3390_pharma3010009 crossref_primary_10_1016_j_ijcard_2010_08_037 crossref_primary_10_1016_j_arteri_2014_09_004 crossref_primary_10_1016_S0828_282X_06_70310_5 crossref_primary_10_1111_j_1365_2265_2008_03490_x crossref_primary_10_1016_j_metabol_2025_156173 crossref_primary_10_2337_dc13_S011 crossref_primary_10_1111_j_1751_7176_2012_00652_x crossref_primary_10_2337_dc16_S011 crossref_primary_10_1016_j_jacc_2008_11_002 crossref_primary_10_1038_s41598_019_55466_3 crossref_primary_10_1159_000445047 crossref_primary_10_1016_j_atherosclerosis_2017_03_032 crossref_primary_10_1016_j_jcjd_2019_07_003 crossref_primary_10_1016_j_atherosclerosis_2016_08_018 crossref_primary_10_1016_S1131_3587_11_70012_7 crossref_primary_10_1097_FJC_0b013e3181624b22 crossref_primary_10_2337_dc12_s011 crossref_primary_10_2165_11319490_000000000_00000 crossref_primary_10_1016_j_repc_2019_03_005 crossref_primary_10_5551_jat_GL2022 crossref_primary_10_1016_j_arteri_2019_10_002 crossref_primary_10_1016_S2173_5093_11_70035_6 crossref_primary_10_1155_2013_653789 crossref_primary_10_1177_0091270009335766 crossref_primary_10_1016_j_avsg_2023_08_023 crossref_primary_10_1093_eurheartj_ehr112 crossref_primary_10_1136_jcp_2008_055756 crossref_primary_10_1186_1471_2377_13_1 crossref_primary_10_1210_er_2018_00064 crossref_primary_10_1161_CIRCRESAHA_115_306398 crossref_primary_10_1097_MOL_0000000000000018 crossref_primary_10_1007_s00018_020_03715_4 crossref_primary_10_1016_S0214_9168_07_74188_8 crossref_primary_10_1016_j_thromres_2007_06_003 crossref_primary_10_1111_j_1464_5491_2007_02111_x crossref_primary_10_1080_00325481_2016_1243005 crossref_primary_10_1016_j_ccl_2014_09_001 crossref_primary_10_1136_pgmj_2010_204990rep crossref_primary_10_1016_S1134_3230_10_63014_1 crossref_primary_10_1016_j_diabres_2022_109835 crossref_primary_10_3390_ph17030289 crossref_primary_10_3390_nu5030981 crossref_primary_10_1056_NEJMoa0706245 crossref_primary_10_2337_dc08_s260 crossref_primary_10_1097_MOL_0b013e3280106208 crossref_primary_10_1186_1471_2369_15_180 crossref_primary_10_5551_jat_RV22013 crossref_primary_10_1007_s11428_012_0891_4 crossref_primary_10_2337_dc20_1533 crossref_primary_10_3389_fcvm_2022_913869 crossref_primary_10_1093_eurjpc_zwad297 crossref_primary_10_1111_dom_12277 crossref_primary_10_1042_BSR20212355 crossref_primary_10_1080_14656566_2017_1285905 crossref_primary_10_1002_clc_4960290609 crossref_primary_10_1080_00325481_2021_1921491 crossref_primary_10_1080_00325481_2020_1783937 crossref_primary_10_1038_ncpendmet0397 crossref_primary_10_2165_11539500_000000000_00000 crossref_primary_10_1097_MD_0000000000003247 crossref_primary_10_4137_CMT_S2036 crossref_primary_10_5551_jat_GL2017 crossref_primary_10_1111_bph_13055 crossref_primary_10_1016_j_ejim_2011_12_007 crossref_primary_10_1007_s11883_020_00846_8 crossref_primary_10_1016_S1155_1941_10_51267_8 crossref_primary_10_1038_nrneph_2016_75 crossref_primary_10_1016_j_pop_2012_11_003 crossref_primary_10_1016_j_foodchem_2012_03_043 crossref_primary_10_1258_acb_2010_010081 crossref_primary_10_1155_2009_460764 crossref_primary_10_1016_j_ddstr_2008_05_004 crossref_primary_10_1007_s12325_017_0586_8 crossref_primary_10_1016_j_jacl_2024_12_017 crossref_primary_10_1530_EC_18_0010 crossref_primary_10_1111_j_1742_1241_2007_01570_x crossref_primary_10_1161_ATVBAHA_108_178228 crossref_primary_10_1111_j_1365_2362_2009_02222_x crossref_primary_10_1016_S1474_4422_12_70005_4 crossref_primary_10_1016_j_jacl_2015_04_004 crossref_primary_10_1093_eurheartj_ehr158 crossref_primary_10_1185_03007995_2010_542081 crossref_primary_10_1042_CS20100508 crossref_primary_10_1007_s11883_010_0126_3 crossref_primary_10_1093_eurheartj_ehr154 crossref_primary_10_1007_s00508_015_0933_1 crossref_primary_10_1016_j_endonu_2010_05_010 crossref_primary_10_1155_2012_302495 crossref_primary_10_3810_pgm_2010_05_2138 crossref_primary_10_2337_dc07_9917 crossref_primary_10_1136_heartjnl_2014_306691 crossref_primary_10_1016_j_atherosclerosis_2024_118552 crossref_primary_10_1080_14656566_2023_2206015 crossref_primary_10_1016_j_clinthera_2005_12_004 crossref_primary_10_1016_j_tem_2006_07_004 crossref_primary_10_1161_CIR_0b013e31820d8c98 crossref_primary_10_1016_j_tem_2006_07_006 crossref_primary_10_1016_j_diabres_2021_109180 crossref_primary_10_1093_eurheartj_ehab484 crossref_primary_10_1111_dom_14046 crossref_primary_10_3390_biomedicines10040876 crossref_primary_10_1007_s10554_014_0370_7 crossref_primary_10_1016_j_jdiacomp_2014_07_002 crossref_primary_10_1111_ceo_12539 crossref_primary_10_3810_pgm_2010_05_2143 crossref_primary_10_4254_wjh_v5_i9_470 crossref_primary_10_1373_clinchem_2016_270876 crossref_primary_10_2337_dc20_S010 crossref_primary_10_1111_dom_13191 crossref_primary_10_1038_nrcardio_2017_11 crossref_primary_10_1016_j_plabm_2021_e00248 crossref_primary_10_1007_s13340_020_00471_5 crossref_primary_10_1016_j_semcancer_2020_11_012 crossref_primary_10_1038_s41574_022_00776_2 crossref_primary_10_1016_j_atherosclerosissup_2008_05_007 crossref_primary_10_1097_01_prs_0000225459_93750_29 crossref_primary_10_1007_s00108_012_3129_z crossref_primary_10_1210_clinem_dgaa361 crossref_primary_10_1002_clc_20226 crossref_primary_10_1111_j_1538_7836_2008_03235_x crossref_primary_10_1016_j_ccl_2008_06_005 crossref_primary_10_1016_S1567_5688_17_30024_7 crossref_primary_10_1345_aph_1R127 crossref_primary_10_3390_cancers13143473 crossref_primary_10_1007_s00508_019_1444_2 crossref_primary_10_1080_17425255_2020_1749261 crossref_primary_10_4239_wjd_v8_i6_235 crossref_primary_10_2217_clp_11_46 crossref_primary_10_1161_HYPERTENSIONAHA_107_108530 crossref_primary_10_1517_14656566_8_9_1345 crossref_primary_10_1038_nrcardio_2010_208 crossref_primary_10_1111_j_1365_2796_2008_01933_x crossref_primary_10_2217_14796678_2_6_635 crossref_primary_10_1186_1475_2840_13_26 crossref_primary_10_1007_s00125_024_06100_z crossref_primary_10_1111_j_1464_5491_2006_1930_3_x crossref_primary_10_1002_pdi_1511 crossref_primary_10_1016_S0084_3741_10_79553_6 crossref_primary_10_1016_j_arteri_2015_02_004 crossref_primary_10_1016_j_cca_2020_09_012 crossref_primary_10_1038_labinvest_2014_80 crossref_primary_10_1038_nrcardio_2017_31 crossref_primary_10_1089_jwh_2019_8189 crossref_primary_10_1007_s11892_006_0006_y crossref_primary_10_1111_jvim_14744 crossref_primary_10_1002_ange_201505111 crossref_primary_10_1080_14779072_2022_2058489 crossref_primary_10_1016_j_arteri_2016_12_001 crossref_primary_10_2217_clp_11_32 crossref_primary_10_1016_S0828_282X_08_71036_5 crossref_primary_10_1186_s12933_024_02161_x crossref_primary_10_2217_fca_2020_0106 crossref_primary_10_1111_dme_12169 crossref_primary_10_1097_MOL_0000000000000426 crossref_primary_10_1186_s12933_015_0226_z crossref_primary_10_1007_s40265_013_0023_5 crossref_primary_10_1080_07853890701379767 crossref_primary_10_1517_14656566_2012_658774 crossref_primary_10_1016_j_amjcard_2011_03_013 crossref_primary_10_1111_j_1751_7176_2011_00451_x crossref_primary_10_1007_s11560_013_0779_3 crossref_primary_10_1007_s11886_018_1068_6 crossref_primary_10_1016_j_jfma_2016_11_013 crossref_primary_10_2337_diaspect_21_3_177 crossref_primary_10_1016_j_diabres_2014_08_029 crossref_primary_10_1016_j_jacl_2008_08_444 crossref_primary_10_1186_1475_2891_13_17 crossref_primary_10_1080_14656566_2024_2347468 crossref_primary_10_1517_14656566_2011_558503 crossref_primary_10_2217_clp_11_28 crossref_primary_10_1111_j_1463_1326_2007_00747_x crossref_primary_10_2337_db13_0800 crossref_primary_10_4093_dmj_2011_35_2_101 crossref_primary_10_5694_mja14_01155 crossref_primary_10_1111_j_1463_1326_2009_01157_x crossref_primary_10_2165_11208090_000000000_00000 crossref_primary_10_1007_s12181_008_0091_z crossref_primary_10_3389_fphar_2023_1190934 crossref_primary_10_1111_jcpt_12423 crossref_primary_10_1016_j_jacl_2017_05_014 crossref_primary_10_1097_MOL_0b013e328012b627 crossref_primary_10_1016_S0214_9168_08_75789_9 crossref_primary_10_1016_j_jcjd_2011_12_001 crossref_primary_10_4103_IJMR_2010_132_05_584 crossref_primary_10_1586_eem_09_46 crossref_primary_10_12997_jla_2021_10_1_88 crossref_primary_10_2217_clp_11_15 crossref_primary_10_1016_j_eprac_2022_07_003 crossref_primary_10_1186_1475_2840_5_20 crossref_primary_10_1016_S0140_6736_05_67668_4 crossref_primary_10_1111_j_1742_1241_2007_01596_x crossref_primary_10_1016_j_mayocp_2018_08_007 crossref_primary_10_1016_j_mcna_2012_01_001 crossref_primary_10_1111_j_1559_4564_2007_06108_x crossref_primary_10_1186_s13098_017_0251_z crossref_primary_10_3892_etm_2018_7046 crossref_primary_10_15829_1560_4071_2023_5471 crossref_primary_10_1016_j_ijcard_2016_06_148 crossref_primary_10_1093_eurheartj_suaa116 crossref_primary_10_1371_journal_pmed_1000196 crossref_primary_10_1038_ng_2795 crossref_primary_10_1373_clinchem_2007_099747 crossref_primary_10_1515_cclm_2012_0078 crossref_primary_10_1016_S1885_5857_07_60149_2 crossref_primary_10_1016_j_jacl_2015_02_004 crossref_primary_10_1101_cshperspect_a040980 crossref_primary_10_1253_circj_CJ_19_0358 crossref_primary_10_2169_naika_112_181 crossref_primary_10_1007_s00109_007_0257_3 crossref_primary_10_1016_j_exger_2019_01_014 crossref_primary_10_1038_nrneph_2018_9 crossref_primary_10_1016_j_biocel_2007_12_001 crossref_primary_10_1089_met_2006_4_328 crossref_primary_10_1016_S0140_6736_06_69700_6 crossref_primary_10_1053_j_ajkd_2008_02_307 crossref_primary_10_1016_j_atherosclerosis_2013_07_003 crossref_primary_10_1002_clc_23437 crossref_primary_10_12997_jla_2019_8_2_221 crossref_primary_10_33590_emjcardiol_20_00038 crossref_primary_10_1016_j_ebiom_2016_09_025 crossref_primary_10_1007_s11886_010_0137_2 crossref_primary_10_1097_MOL_0b013e328342b0e9 crossref_primary_10_1016_S1166_4568_07_37918_7 crossref_primary_10_1016_S1262_3636_07_80038_3 crossref_primary_10_1016_j_jacl_2017_10_006 crossref_primary_10_1016_j_ejphar_2024_176767 crossref_primary_10_1161_HYPERTENSIONAHA_109_149146 crossref_primary_10_1093_ije_dyq012 crossref_primary_10_1016_j_clinthera_2021_08_005 crossref_primary_10_1016_j_jjcc_2017_09_001 crossref_primary_10_2337_dc23_S010 crossref_primary_10_1007_s00125_014_3344_3 crossref_primary_10_1007_s00125_010_1854_1 crossref_primary_10_1002_prca_201000076 crossref_primary_10_1186_s12944_017_0592_5 crossref_primary_10_1016_j_arteri_2011_07_003 crossref_primary_10_1016_j_diabres_2010_03_019 crossref_primary_10_1016_j_yjmcc_2023_12_008 crossref_primary_10_1097_00005082_200611001_00004 crossref_primary_10_1136_bmjopen_2017_015935 crossref_primary_10_2169_internalmedicine_6893_20 crossref_primary_10_2217_17460875_2_2_157 crossref_primary_10_1177_1740774511432726 crossref_primary_10_1161_CIR_0000000000000766 crossref_primary_10_1111_j_1472_8206_2010_00834_x crossref_primary_10_1185_030079906X154169 crossref_primary_10_1007_s10557_008_6160_5 crossref_primary_10_1016_j_ecl_2015_09_012 crossref_primary_10_1194_jlr_M075648 crossref_primary_10_1016_j_ecl_2022_02_004 crossref_primary_10_3389_fendo_2024_1333553 crossref_primary_10_1016_j_diabres_2020_108450 crossref_primary_10_1016_j_atherosclerosis_2011_04_020 crossref_primary_10_1002_pds_1617 crossref_primary_10_1016_j_ahj_2007_11_029 crossref_primary_10_1253_circj_72_218 crossref_primary_10_1016_j_acvd_2008_10_001 crossref_primary_10_22516_25007440_350 crossref_primary_10_1016_j_beem_2014_01_006 crossref_primary_10_1016_j_tcm_2021_04_007 crossref_primary_10_1007_s13340_015_0206_2 crossref_primary_10_1111_j_1463_1326_2008_00917_x crossref_primary_10_51789_cmsj_2021_1_e2 crossref_primary_10_1161_ATVBAHA_112_300665 crossref_primary_10_1177_14746514060060030301 crossref_primary_10_3389_fmed_2020_00065 crossref_primary_10_1016_j_jdiacomp_2023_108517 crossref_primary_10_1016_j_molmed_2019_05_010 crossref_primary_10_3390_jcm12041481 crossref_primary_10_3390_biom12020242 crossref_primary_10_1016_j_jacc_2006_04_097 crossref_primary_10_1038_nrcardio_2010_162 crossref_primary_10_1177_0003319711401012 crossref_primary_10_1097_MLR_0b013e3181844855 crossref_primary_10_1371_journal_pone_0053224 crossref_primary_10_1155_2016_4351376 crossref_primary_10_2165_11318270_000000000_00000 crossref_primary_10_20945_2359_3997000000585 crossref_primary_10_1016_j_jcjd_2017_10_019 crossref_primary_10_3390_jcm14030683 crossref_primary_10_2337_db08_0226 crossref_primary_10_1371_journal_pone_0038072 crossref_primary_10_5551_jat_ER39693 crossref_primary_10_1177_1740774511410995 crossref_primary_10_2337_dc11_s256 crossref_primary_10_3928_23258160_20240729_03 crossref_primary_10_1097_XCE_0000000000000120 crossref_primary_10_1161_CIR_0b013e31820d8d78 crossref_primary_10_1016_S1131_3587_08_73551_9 crossref_primary_10_1016_j_atherosclerosis_2011_11_030 crossref_primary_10_1097_HCO_0b013e32832c0b3d crossref_primary_10_1016_j_endinu_2022_03_004 crossref_primary_10_1177_0003319711409391 crossref_primary_10_1007_s15202_015_0641_8 crossref_primary_10_1002_clc_22137 crossref_primary_10_1111_imj_16270 crossref_primary_10_1186_s12944_020_01415_3 crossref_primary_10_1016_j_dld_2010_02_004 crossref_primary_10_1007_s40265_022_01691_6 crossref_primary_10_2215_CJN_0000000000000159 crossref_primary_10_5694_mja16_00650 crossref_primary_10_1038_s41569_020_0339_2 crossref_primary_10_1021_jm8003416 crossref_primary_10_3999_jscpt_43_375 crossref_primary_10_1007_s11892_006_0040_9 crossref_primary_10_1007_s00125_007_0801_2 crossref_primary_10_2217_17460875_2_2_197 crossref_primary_10_1016_j_ijcard_2016_07_239 crossref_primary_10_1097_MED_0000000000000594 crossref_primary_10_3390_jcm13010168 crossref_primary_10_1016_j_phrs_2023_106738 crossref_primary_10_1016_S0214_9168_16_30084_5 crossref_primary_10_1097_HCO_0000000000000407 crossref_primary_10_1016_j_diabres_2015_12_002 crossref_primary_10_1007_s11883_007_0033_4 crossref_primary_10_1016_j_dsx_2012_02_018 crossref_primary_10_3390_jcm10112233 crossref_primary_10_1080_17512433_2019_1567328 crossref_primary_10_1177_2047487318816495 crossref_primary_10_1310_hct0801_45 crossref_primary_10_2337_dc21_1977 crossref_primary_10_2337_dc09_S343 crossref_primary_10_2337_dc09_S345 crossref_primary_10_3390_ph17050568 crossref_primary_10_1111_j_1753_0407_2011_00113_x crossref_primary_10_1016_j_atherosclerosis_2006_02_036 crossref_primary_10_5551_jat_992 crossref_primary_10_1080_17512433_2018_1425138 crossref_primary_10_1016_S2173_5093_11_70061_7 crossref_primary_10_1016_j_cca_2013_12_022 crossref_primary_10_1177_0897190010392235 crossref_primary_10_1185_03007995_2013_766592 crossref_primary_10_1161_CIRCULATIONAHA_105_563213 crossref_primary_10_2217_17460875_1_5_579 crossref_primary_10_2337_dc11_s203 crossref_primary_10_2169_naika_95_1932 crossref_primary_10_1001_jama_2018_20045 crossref_primary_10_1016_j_exer_2007_01_009 crossref_primary_10_1016_j_jacl_2012_04_079 crossref_primary_10_1007_s40620_020_00739_8 crossref_primary_10_1016_j_diabet_2010_01_001 crossref_primary_10_1161_ATVBAHA_107_155739 crossref_primary_10_2217_fca_13_4 crossref_primary_10_1007_s00392_017_1106_1 crossref_primary_10_1016_S0300_8932_10_70091_9 crossref_primary_10_1007_s10557_023_07519_z crossref_primary_10_1161_CIRCULATIONAHA_105_590273 crossref_primary_10_2337_dc06_0255 crossref_primary_10_1111_j_1600_6143_2012_04084_x crossref_primary_10_1038_bjp_2008_331 crossref_primary_10_1111_j_1524_6175_2007_06639_x crossref_primary_10_1152_ajprenal_00484_2007 crossref_primary_10_1002_edm2_126 crossref_primary_10_1016_j_addr_2020_04_013 crossref_primary_10_2174_1570161117666190507110519 crossref_primary_10_1007_s00717_016_0300_2 crossref_primary_10_1111_dom_15815 crossref_primary_10_3390_ijms20102521 crossref_primary_10_1038_s41598_020_78676_6 crossref_primary_10_3803_EnM_2013_28_3_169 crossref_primary_10_1097_MAJ_0b013e31821483fa crossref_primary_10_1002_sim_6960 crossref_primary_10_2337_dc08_2335 crossref_primary_10_1157_13123996 crossref_primary_10_1038_nrendo_2010_128 crossref_primary_10_2147_nano_2006_1_2_129 crossref_primary_10_3109_13697137_2012_656401 crossref_primary_10_1001_jamainternmed_2021_5726 crossref_primary_10_2174_1381612825666191126102943 crossref_primary_10_1093_eurheartj_ehw272 crossref_primary_10_1111_jdi_14290 crossref_primary_10_1155_2008_245410 crossref_primary_10_1016_j_clinthera_2011_02_006 crossref_primary_10_2217_fca_12_25 crossref_primary_10_2459_JCM_0b013e32834bb3c8 crossref_primary_10_3390_jpm10030070 crossref_primary_10_4158_EP14396_RA crossref_primary_10_1016_S1155_1941_11_51216_8 crossref_primary_10_1517_17460440903008510 crossref_primary_10_1517_14656566_9_13_2295 crossref_primary_10_1016_j_metabol_2015_12_008 crossref_primary_10_1002_clc_23055 crossref_primary_10_1038_nrneph_2014_87 crossref_primary_10_1016_j_phrs_2020_104916 crossref_primary_10_1016_j_arteri_2011_09_005 crossref_primary_10_1586_14779072_2014_942640 crossref_primary_10_3390_cells10113259 crossref_primary_10_2165_00002512_200825080_00003 crossref_primary_10_1016_S0140_6736_08_60335_9 crossref_primary_10_1016_j_amjcard_2006_01_062 crossref_primary_10_1016_j_amjcard_2006_01_061 crossref_primary_10_1159_000453626 crossref_primary_10_3390_jcm11030768 crossref_primary_10_1517_14712598_7_1_53 crossref_primary_10_1016_j_ccl_2021_04_008 crossref_primary_10_1016_j_arteri_2020_12_012 crossref_primary_10_1016_j_jdiacomp_2023_108597 crossref_primary_10_1016_S1634_7072_24_48980_0 crossref_primary_10_3390_biomedicines10051180 crossref_primary_10_1016_j_dib_2016_04_059 crossref_primary_10_1038_clpt_2011_271 crossref_primary_10_1016_j_tips_2015_11_009 crossref_primary_10_1016_S1155_1941_10_51265_4 crossref_primary_10_1111_jdi_14284 crossref_primary_10_1111_j_1559_4572_2009_00060_x crossref_primary_10_2174_1389200219666180611083155 crossref_primary_10_1016_S2213_8587_20_30367_3 crossref_primary_10_2337_dc07_0732 crossref_primary_10_4093_jkd_2015_16_2_89 crossref_primary_10_1016_j_atherosclerosis_2013_07_041 crossref_primary_10_1097_MAJ_0b013e31815d4419 crossref_primary_10_1016_j_eclnm_2008_02_001 crossref_primary_10_1038_sj_clpt_6100254 crossref_primary_10_2337_dc14_S014 crossref_primary_10_1016_j_clinbiochem_2006_11_010 crossref_primary_10_3132_dvdr_2007_067 crossref_primary_10_5604_01_3001_0015_4805 crossref_primary_10_1016_j_biopha_2019_108722 crossref_primary_10_1007_s00415_007_0569_9 crossref_primary_10_5551_jat_10454 crossref_primary_10_1007_s00125_012_2818_4 crossref_primary_10_1016_j_bbamem_2020_183254 crossref_primary_10_1016_j_jacl_2014_05_003 crossref_primary_10_1038_s42003_022_03300_4 crossref_primary_10_3132_dvdr_2007_069 crossref_primary_10_1177_0091270010382914 crossref_primary_10_1016_S1499_2671_06_03007_3 crossref_primary_10_12997_jla_2013_2_2_53 crossref_primary_10_33678_cor_2006_053 crossref_primary_10_38109_2225_1685_2020_2_6_29 crossref_primary_10_1080_14656566_2025_2451752 crossref_primary_10_1038_ki_2013_335 crossref_primary_10_1089_met_2012_1500 crossref_primary_10_2337_dc16_0155 crossref_primary_10_2337_dc08_0118 crossref_primary_10_5551_jat_10447 crossref_primary_10_3132_dvdr_2007_051 crossref_primary_10_1186_1758_5996_6_113 crossref_primary_10_3132_dvdr_2007_053 crossref_primary_10_1080_13543784_2019_1696772 crossref_primary_10_1111_j_1365_2125_2012_04211_x crossref_primary_10_1136_bmjdrc_2023_003414 crossref_primary_10_3390_jcm10204666 crossref_primary_10_1016_j_cger_2009_09_001 crossref_primary_10_1016_j_tjnut_2024_01_007 crossref_primary_10_1007_s11886_020_01326_w crossref_primary_10_1016_j_jacc_2007_01_067 crossref_primary_10_1124_mol_108_052928 crossref_primary_10_1007_s00125_010_1806_9 crossref_primary_10_1111_dom_13646 crossref_primary_10_1111_j_1472_8206_2009_00764_x crossref_primary_10_1111_j_1742_1241_2009_02053_x crossref_primary_10_21518_ms2023_268 crossref_primary_10_33667_2078_5631_2021_17_13_19 crossref_primary_10_1097_MD_0000000000012587 crossref_primary_10_1161_STROKEAHA_106_474791 crossref_primary_10_1161_CIRCULATIONAHA_116_022194 crossref_primary_10_1016_j_alcohol_2014_08_004 crossref_primary_10_1136_ebm1118 crossref_primary_10_2165_00129784_200808040_00004 crossref_primary_10_1016_j_mcna_2007_06_008 crossref_primary_10_1016_S2213_8587_18_30029_9 crossref_primary_10_1016_j_diabres_2022_110091 crossref_primary_10_1093_eurjpc_zwab154 crossref_primary_10_1093_eurjpc_zwad331 crossref_primary_10_3132_dvdr_2007_040 crossref_primary_10_3132_dvdr_2007_041 crossref_primary_10_3390_nu14163277 crossref_primary_10_1016_j_ccl_2010_11_004 crossref_primary_10_1371_journal_pone_0023589 crossref_primary_10_1016_S1134_3230_10_64001_X crossref_primary_10_2337_dci15_0012 crossref_primary_10_1016_j_jacl_2011_09_004 crossref_primary_10_3132_dvdr_2007_042 crossref_primary_10_1517_13543784_17_10_1599 crossref_primary_10_3390_ijms20225682 crossref_primary_10_2337_db22_0611 crossref_primary_10_1016_j_ahj_2010_10_019 crossref_primary_10_2337_dc24_S010 crossref_primary_10_3132_dvdr_2007_039 crossref_primary_10_1002_gepi_22149 crossref_primary_10_1016_j_atherosclerosis_2006_10_017 crossref_primary_10_2174_1874192401004010120 crossref_primary_10_1016_j_ypmed_2016_01_004 crossref_primary_10_1254_jphs_11097FP crossref_primary_10_1007_s10557_014_6534_9 crossref_primary_10_1016_j_phrs_2006_03_012 crossref_primary_10_1016_S0140_6736_09_60698_X crossref_primary_10_1161_01_ATV_0000242904_34700_66 crossref_primary_10_1016_S0828_282X_06_70301_4 crossref_primary_10_3390_diseases11040140 crossref_primary_10_1586_17446651_2013_846212 crossref_primary_10_1097_XEB_0000000000000121 crossref_primary_10_1111_dom_14502 crossref_primary_10_3945_ajcn_114_096925 crossref_primary_10_3132_dvdr_2007_033 crossref_primary_10_1007_s11883_008_0005_3 crossref_primary_10_3132_dvdr_2007_032 crossref_primary_10_1161_01_cir_0000437738_63853_7a crossref_primary_10_1016_j_ijcard_2008_11_211 crossref_primary_10_1080_14656566_2021_1912734 crossref_primary_10_1016_j_clinthera_2015_08_001 crossref_primary_10_1136_postgradmedj_2011_130594 crossref_primary_10_1097_MOL_0b013e32833ee80c crossref_primary_10_1161_STR_0000000000000046 crossref_primary_10_1016_j_vph_2014_11_002 crossref_primary_10_1016_S1131_3587_06_74826_9 crossref_primary_10_1097_FJC_0b013e31817ffe5a crossref_primary_10_1016_j_amjopharm_2006_03_010 crossref_primary_10_1016_j_phrs_2014_02_007 crossref_primary_10_1186_2193_1801_3_14 crossref_primary_10_1016_j_exer_2015_08_010 crossref_primary_10_1016_j_ecl_2017_10_004 crossref_primary_10_1016_j_jss_2013_06_029 crossref_primary_10_1007_s11883_016_0593_2 crossref_primary_10_1016_j_coph_2018_01_003 crossref_primary_10_3132_dvdr_2007_020 crossref_primary_10_1177_1474651410397245 crossref_primary_10_1210_jc_2009_1487 crossref_primary_10_1007_s15034_017_0972_y crossref_primary_10_1016_j_ando_2016_01_005 crossref_primary_10_1515_cclm_2012_0372 crossref_primary_10_1097_01_NAJ_0000511539_37103_0b crossref_primary_10_1002_hep_27744 crossref_primary_10_1097_MOL_0b013e328321b3be crossref_primary_10_1016_S0246_0343_06_44024_7 crossref_primary_10_3390_life11111168 crossref_primary_10_1289_ehp_0900758 crossref_primary_10_1177_0897190006290046 crossref_primary_10_1177_0897190006290045 crossref_primary_10_4082_kjfm_2017_38_4_192 crossref_primary_10_1097_MOL_0b013e328306596d crossref_primary_10_25207_1608_6228_2019_26_1_209_218 crossref_primary_10_1097_HJH_0000000000002693 crossref_primary_10_1007_s11883_022_01079_7 crossref_primary_10_1007_s10557_009_6190_7 crossref_primary_10_1016_j_biopha_2016_11_114 crossref_primary_10_1111_dom_13689 crossref_primary_10_1111_imj_15733 crossref_primary_10_1161_CIRCULATIONAHA_106_637793 crossref_primary_10_1016_j_plipres_2014_07_002 crossref_primary_10_1111_j_1520_037X_2006_4992_x crossref_primary_10_1016_j_oret_2017_05_010 crossref_primary_10_1111_j_1463_1326_2011_01509_x crossref_primary_10_1016_j_clinthera_2007_05_002 crossref_primary_10_1124_jpet_108_143271 crossref_primary_10_3389_fpubh_2020_532719 crossref_primary_10_3390_ijms23073418 crossref_primary_10_1038_eye_2008_428 crossref_primary_10_1136_jnis_2011_004762 crossref_primary_10_1016_j_jacc_2008_03_025 crossref_primary_10_1038_s41569_021_00569_6 crossref_primary_10_1038_s41440_023_01175_4 crossref_primary_10_1007_s11886_018_0997_4 crossref_primary_10_1152_ajpendo_00627_2007 crossref_primary_10_12968_pnur_2012_23_2_82 crossref_primary_10_1007_BF02938374 crossref_primary_10_1007_s11154_014_9298_4 crossref_primary_10_1097_01_hco_0000231412_15049_fb crossref_primary_10_1161_01_STR_0000257974_06317_49 crossref_primary_10_1177_2042018810376023 crossref_primary_10_12997_jla_2017_6_2_89 crossref_primary_10_1002_hep_25580 crossref_primary_10_1007_s11892_016_0786_7 crossref_primary_10_1056_NEJMp1508120 crossref_primary_10_1161_CIRCULATIONAHA_118_039107 crossref_primary_10_1111_j_1524_6175_2006_05505_x crossref_primary_10_1016_j_jacl_2010_08_004 crossref_primary_10_1080_14728222_2022_2161887 crossref_primary_10_1007_s40266_018_00632_x crossref_primary_10_1093_cvr_cvn354 crossref_primary_10_3389_fphar_2017_00835 crossref_primary_10_1016_j_jcjd_2015_09_012 crossref_primary_10_1186_s12879_017_2626_z crossref_primary_10_1373_clinchem_2007_101923 crossref_primary_10_1007_s00125_023_06008_0 crossref_primary_10_1097_MOL_0b013e32834701c3 crossref_primary_10_2146_ajhp070659 crossref_primary_10_3390_ijms231810814 crossref_primary_10_1016_j_jacc_2010_01_008 crossref_primary_10_1080_14779072_2017_1408410 crossref_primary_10_1111_dom_13691 crossref_primary_10_1111_j_1524_6175_2005_05278_x crossref_primary_10_1016_j_ahj_2010_06_045 crossref_primary_10_1007_s11886_016_0795_9 crossref_primary_10_1007_s11428_018_0393_0 crossref_primary_10_1038_s41433_024_03022_3 crossref_primary_10_1016_j_semnephrol_2018_05_007 crossref_primary_10_1007_s10620_017_4812_7 crossref_primary_10_1111_jdi_13306 crossref_primary_10_1038_ncpendmet0293 crossref_primary_10_3390_ijms19041197 crossref_primary_10_1016_j_vph_2015_06_014 crossref_primary_10_1002_pds_70047 crossref_primary_10_1093_eurjpc_zwad391 crossref_primary_10_1097_FJC_0b013e3180544540 crossref_primary_10_1016_j_hbpd_2022_10_004 crossref_primary_10_1002_14651858_CD009580_pub2 crossref_primary_10_1016_j_jacl_2015_11_006 crossref_primary_10_3346_jkms_2023_38_e295 crossref_primary_10_1111_j_1440_1797_2010_01240_x crossref_primary_10_1016_j_revmed_2007_03_012 crossref_primary_10_1007_s40256_016_0179_y crossref_primary_10_1016_j_rce_2014_07_005 crossref_primary_10_1111_j_1742_1241_2008_01794_x crossref_primary_10_2147_CEOR_S377935 crossref_primary_10_1016_j_atherosclerosis_2008_09_027 crossref_primary_10_1007_s11883_022_01013_x crossref_primary_10_1016_j_clinthera_2014_04_017 crossref_primary_10_1016_j_ihj_2014_12_001 crossref_primary_10_1177_2042018810379587 crossref_primary_10_2217_pme_2020_0110 crossref_primary_10_1007_s11883_011_0217_9 crossref_primary_10_1155_2022_3157841 crossref_primary_10_1007_s11883_013_0313_0 crossref_primary_10_1111_j_1365_2796_2007_01828_x crossref_primary_10_1517_13543776_16_12_1713 crossref_primary_10_1186_1741_7015_11_157 crossref_primary_10_1186_s41100_016_0028_0 crossref_primary_10_3390_jcm11102761 crossref_primary_10_1002_jmr_2258 crossref_primary_10_1016_j_carpath_2008_03_001 crossref_primary_10_1016_j_jacl_2015_09_002 crossref_primary_10_1007_s00125_007_0751_8 crossref_primary_10_1016_j_ijcard_2007_06_009 crossref_primary_10_1097_FJC_0b013e318062153b crossref_primary_10_23736_S0026_4806_22_07579_6 crossref_primary_10_2337_dc21_S010 crossref_primary_10_1016_j_pharmthera_2010_02_006 crossref_primary_10_1186_s12933_015_0173_8 crossref_primary_10_5551_jat_62821 crossref_primary_10_3945_an_113_003798 crossref_primary_10_2337_dc09_0621 crossref_primary_10_3310_hta22270 crossref_primary_10_1097_01_hco_0000231404_76930_e9 crossref_primary_10_1007_s11428_011_0691_2 crossref_primary_10_1177_1179551419866811 crossref_primary_10_2217_clp_12_41 crossref_primary_10_1186_1477_7525_5_21 crossref_primary_10_1080_14656566_2020_1801638 crossref_primary_10_1007_s12325_016_0462_y crossref_primary_10_1007_s12170_025_00758_9 crossref_primary_10_1016_j_preteyeres_2020_100903 crossref_primary_10_1080_17512433_2018_1429910 crossref_primary_10_1136_bmj_m3109 crossref_primary_10_3390_nu12020328 crossref_primary_10_2217_14622416_8_6_587 crossref_primary_10_1016_j_clinthera_2008_02_004 crossref_primary_10_1586_erc_09_30 crossref_primary_10_2217_14622416_8_11_1581 crossref_primary_10_1177_1474651406006002S0501 crossref_primary_10_1093_cvr_cvp106 crossref_primary_10_1016_j_burns_2011_12_004 crossref_primary_10_1517_13543784_2010_539559 crossref_primary_10_1253_circj_CJ_20_1037 crossref_primary_10_1016_j_jacc_2008_09_049 crossref_primary_10_1007_s11883_023_01176_1 crossref_primary_10_1177_1479164111407783 crossref_primary_10_1016_j_ejmech_2019_01_067 crossref_primary_10_1016_j_ajpath_2018_03_018 crossref_primary_10_1089_met_2014_0049 crossref_primary_10_1016_j_jacl_2013_08_001 crossref_primary_10_1097_MOL_0000000000000979 crossref_primary_10_1007_s00044_019_02496_1 crossref_primary_10_1097_XCE_0000000000000043 crossref_primary_10_2217_14622416_8_11_1567 crossref_primary_10_5551_jat_62889 crossref_primary_10_1007_s11883_009_0043_5 crossref_primary_10_1517_14656566_2013_850075 crossref_primary_10_1053_j_ajkd_2012_07_005 crossref_primary_10_1111_j_1753_0407_2011_00161_x crossref_primary_10_3390_ijms20133151 crossref_primary_10_1080_13543784_2017_1312339 crossref_primary_10_2169_naika_98_794 crossref_primary_10_5694_j_1326_5377_2006_tb00583_x crossref_primary_10_1186_1471_2288_13_107 crossref_primary_10_1016_j_jacl_2024_07_001 crossref_primary_10_1185_03007995_2014_965774 crossref_primary_10_3810_pgm_2014_05_2762 crossref_primary_10_1210_jc_2011_3213 crossref_primary_10_1258_acb_2009_200918 crossref_primary_10_1007_s12170_018_0566_9 crossref_primary_10_1161_ATV_0000000000000073 crossref_primary_10_2337_dc08_1809 crossref_primary_10_3390_jpm13010068 crossref_primary_10_1093_qjmed_hcp065 crossref_primary_10_1097_MJT_0b013e3181dcf72b crossref_primary_10_1097_HCO_0b013e32832ebfe7 crossref_primary_10_1016_j_beem_2007_08_002 crossref_primary_10_1097_01_NPR_0000526627_04268_80 crossref_primary_10_1016_S1885_5857_08_60212_1 crossref_primary_10_1016_S0300_8932_10_70150_0 crossref_primary_10_1038_nature10146 crossref_primary_10_1016_j_bbrep_2021_101091 crossref_primary_10_1016_j_hipert_2013_01_002 crossref_primary_10_1517_17425255_2010_504715 crossref_primary_10_1586_17446651_2014_941356 crossref_primary_10_2217_clp_12_13 crossref_primary_10_1186_s12933_020_01188_0 crossref_primary_10_1161_ATVBAHA_108_179689 crossref_primary_10_1177_0003319711407628 crossref_primary_10_1016_j_arteri_2016_06_001 crossref_primary_10_1016_j_atherosclerosis_2015_06_012 crossref_primary_10_1056_EVIDoa2400179 crossref_primary_10_1586_erc_10_45 crossref_primary_10_3904_kjm_2014_86_6_702 crossref_primary_10_1007_s00125_020_05156_x crossref_primary_10_1016_j_amjcard_2015_01_015 crossref_primary_10_1016_j_dsx_2006_11_007 crossref_primary_10_1038_nrneph_2010_59 crossref_primary_10_1177_1479164110383723 crossref_primary_10_2165_00003088_200746020_00001 crossref_primary_10_14341_2072_0351_5638 crossref_primary_10_1007_s13116_010_0037_z crossref_primary_10_1161_CIRCULATIONAHA_120_046361 crossref_primary_10_1111_fcp_12406 crossref_primary_10_1161_ATVBAHA_115_306442 crossref_primary_10_1111_dme_15310 crossref_primary_10_1007_s10557_021_07168_0 crossref_primary_10_1016_S0025_6196_11_60770_2 crossref_primary_10_1186_s12933_014_0135_6 crossref_primary_10_1007_s00125_012_2524_2 crossref_primary_10_1586_ecp_11_64 crossref_primary_10_1016_j_febslet_2009_03_038 crossref_primary_10_1016_j_endonu_2010_10_004 crossref_primary_10_1053_j_ajkd_2009_03_022 crossref_primary_10_1016_j_jacc_2010_01_053 crossref_primary_10_1016_S1885_5857_08_60234_0 crossref_primary_10_1007_s10557_012_6394_0 crossref_primary_10_1007_s11883_009_0012_z crossref_primary_10_1038_nrd2005 crossref_primary_10_1038_nrd2489 crossref_primary_10_1111_bph_12475 crossref_primary_10_3390_nu14051066 crossref_primary_10_4103_0022_3859_97176 crossref_primary_10_1016_j_diabet_2010_10_001 crossref_primary_10_1097_01_crd_0000240528_66999_ed crossref_primary_10_1517_14740338_2013_741585 crossref_primary_10_1684_bdc_2014_1887 crossref_primary_10_1016_j_metabol_2010_04_020 crossref_primary_10_1080_08998280_2007_11928321 crossref_primary_10_4093_dmj_2020_0001 crossref_primary_10_1080_14740338_2021_1915984 crossref_primary_10_4158_EP15672_GLSUPPL crossref_primary_10_5551_jat_39693 crossref_primary_10_1016_j_atherosclerosis_2015_04_005 crossref_primary_10_1155_2008_891425 crossref_primary_10_1592_phco_27_3_412 crossref_primary_10_1016_j_diabres_2011_02_007 crossref_primary_10_1111_j_1463_1326_2009_01134_x crossref_primary_10_15789_1563_0625_PEO_2222 crossref_primary_10_1016_j_jash_2007_12_007 crossref_primary_10_1016_j_revmed_2007_01_022 crossref_primary_10_1161_CIRCULATIONAHA_117_027252 crossref_primary_10_1517_14728214_13_3_447 crossref_primary_10_1007_s11883_020_0823_5 crossref_primary_10_1016_j_amjcard_2012_05_031 crossref_primary_10_3390_jcm12041382 crossref_primary_10_1080_14656566_2017_1351946 crossref_primary_10_1007_s11428_018_0362_7 crossref_primary_10_1016_j_ijcard_2008_03_080 crossref_primary_10_3109_s10165_009_0261_2 crossref_primary_10_1016_j_clinthera_2013_07_420 crossref_primary_10_1097_MOL_0000000000000528 crossref_primary_10_1517_14712598_2012_641531 crossref_primary_10_1517_14656566_2012_690395 crossref_primary_10_1517_14728222_2016_1152264 crossref_primary_10_1016_j_pharmthera_2009_03_003 crossref_primary_10_5551_jat_61101 crossref_primary_10_12997_jla_2013_2_1_1 crossref_primary_10_2337_dc06_1961 crossref_primary_10_1016_j_atherosclerosis_2010_05_006 crossref_primary_10_1016_j_therap_2018_10_001 crossref_primary_10_1093_bioadv_vbad148 crossref_primary_10_1016_j_hlc_2014_11_016 crossref_primary_10_1016_S1262_3636_07_70310_5 crossref_primary_10_1586_ecp_11_73 crossref_primary_10_1016_j_atherosclerosis_2006_08_005 crossref_primary_10_1002_phar_1268 crossref_primary_10_2337_db17_0093 crossref_primary_10_1016_j_clnu_2009_03_012 crossref_primary_10_1038_nrendo_2009_213 crossref_primary_10_1038_nrd2476 crossref_primary_10_1007_s10384_010_0913_y crossref_primary_10_1517_14656566_2014_986094 crossref_primary_10_1161_CIRCRESAHA_115_306884 crossref_primary_10_1007_s00125_006_0325_1 crossref_primary_10_1016_j_atherosclerosis_2007_01_023 crossref_primary_10_1161_CIR_0b013e318235eb4d crossref_primary_10_1016_j_ecl_2006_06_002 crossref_primary_10_1007_s13410_020_00819_2 crossref_primary_10_1038_kisup_2013_42 crossref_primary_10_1080_07853890_2018_1498118 crossref_primary_10_21886_2712_8156_2022_3_3_50_59 crossref_primary_10_1186_s12944_017_0625_0 crossref_primary_10_12968_indn_2005_1_12_73978 crossref_primary_10_1517_14656566_8_13_2059 crossref_primary_10_1111_jdi_12810 crossref_primary_10_3109_10408363_2014_937523 crossref_primary_10_1007_s40119_018_0123_0 crossref_primary_10_1016_S0214_9168_16_30085_7 crossref_primary_10_1016_j_pneumo_2008_09_005 crossref_primary_10_1007_s11883_009_0051_5 crossref_primary_10_4093_dmj_2013_37_5_326 crossref_primary_10_1517_14656566_2014_972365 crossref_primary_10_1016_j_diabres_2011_05_034 crossref_primary_10_1056_NEJMoa2210645 crossref_primary_10_2174_1570180817999201016154400 crossref_primary_10_3390_metabo13050626 crossref_primary_10_1016_j_ahj_2011_12_004 crossref_primary_10_1016_j_jacl_2010_04_003 crossref_primary_10_1097_QAI_0b013e3182a60e82 crossref_primary_10_1038_kisup_2013_37 crossref_primary_10_1002_pdi_1210 crossref_primary_10_1002_clc_22692 crossref_primary_10_1592_phco_26_7part2_98S crossref_primary_10_1007_s11892_009_0004_y crossref_primary_10_1016_j_jcjd_2013_01_032 crossref_primary_10_2337_db20_0635 crossref_primary_10_1111_j_1365_2796_2007_01898_x crossref_primary_10_1186_s13063_022_06393_8 crossref_primary_10_3390_metabo13050621 crossref_primary_10_1097_HCO_0000000000000331 crossref_primary_10_2165_10898610_000000000_00000 crossref_primary_10_3390_biomedicines9091255 crossref_primary_10_2337_dc08_9018 crossref_primary_10_1016_j_recesp_2013_10_015 crossref_primary_10_1177_0091270011416937 crossref_primary_10_1016_j_ijcard_2007_04_040 crossref_primary_10_1007_s12020_021_02671_8 crossref_primary_10_4158_CS_2020_0490 crossref_primary_10_1016_j_diabres_2024_111612 crossref_primary_10_1002_cmdc_200800425 crossref_primary_10_1016_j_atherosclerosis_2015_12_018 crossref_primary_10_1097_MOL_0b013e3281574570 crossref_primary_10_1111_j_1559_4564_2006_05487_x crossref_primary_10_1007_s00125_010_1951_1 crossref_primary_10_1016_j_ejim_2017_04_017 crossref_primary_10_1111_j_1463_1326_2010_01231_x crossref_primary_10_1016_S1957_2557_19_30041_0 crossref_primary_10_1161_ATVBAHA_107_158998 crossref_primary_10_1016_j_endonu_2010_06_003 crossref_primary_10_1016_j_preteyeres_2015_04_003 crossref_primary_10_1161_CIR_0b013e3182160726 crossref_primary_10_1590_0001_3765202220201909 crossref_primary_10_3390_metabo11060372 crossref_primary_10_1002_jnr_24709 crossref_primary_10_1038_nrcardio_2013_15_c1 crossref_primary_10_1152_ajpendo_00284_2010 crossref_primary_10_1097_HJR_0b013e32832c8891 crossref_primary_10_2337_db19_0862 crossref_primary_10_1016_j_ahj_2006_10_031 crossref_primary_10_1161_HYPERTENSIONAHA_118_11130 crossref_primary_10_1016_j_pcad_2016_07_011 crossref_primary_10_1007_s11428_016_0068_7 crossref_primary_10_1007_s12170_022_00702_1 crossref_primary_10_1586_17512433_2015_1045880 crossref_primary_10_1016_j_atherosclerosis_2006_08_041 crossref_primary_10_1016_j_ahj_2018_09_011 crossref_primary_10_1007_s12471_017_0959_2 crossref_primary_10_1007_s00467_015_3169_4 crossref_primary_10_3390_biomedicines8100433 crossref_primary_10_1007_s11886_008_0076_3 crossref_primary_10_1517_14656566_2010_513116 crossref_primary_10_1016_j_yexcr_2021_112753 crossref_primary_10_2337_dc08_1543 crossref_primary_10_1161_JAHA_111_000059 crossref_primary_10_1007_s15027_014_0520_9 crossref_primary_10_1007_s13300_016_0167_x crossref_primary_10_1371_journal_pone_0154683 crossref_primary_10_1157_13123045 crossref_primary_10_1016_j_crvasa_2014_02_008 crossref_primary_10_1016_j_dsx_2019_01_043 crossref_primary_10_1016_j_etap_2008_03_012 crossref_primary_10_1080_17425255_2018_1483337 crossref_primary_10_1155_2011_496925 crossref_primary_10_1177_1740774511419685 crossref_primary_10_1681_ASN_2014070688 crossref_primary_10_1097_01_mol_0000252612_21602_e3 crossref_primary_10_1016_j_atherosclerosis_2012_12_001 crossref_primary_10_2165_0129784_200808060_00005 crossref_primary_10_1111_j_1365_2125_2006_02785_x crossref_primary_10_1007_s10557_009_6188_1 crossref_primary_10_1155_2012_504918 crossref_primary_10_1007_s11936_011_0128_7 crossref_primary_10_1016_j_atherosclerosis_2015_03_016 crossref_primary_10_2217_clp_12_81 crossref_primary_10_1177_0141076817712254 crossref_primary_10_2217_clp_12_64 crossref_primary_10_1038_emm_2013_58 crossref_primary_10_2146_ajhp120131 crossref_primary_10_3390_cells11203236 crossref_primary_10_1055_a_1237_6833 crossref_primary_10_1016_j_ijcard_2007_04_080 crossref_primary_10_1016_j_pop_2015_05_005 crossref_primary_10_1016_j_diabet_2010_07_010 crossref_primary_10_1097_FJC_0000000000000891 crossref_primary_10_1097_HCO_0b013e32834965e9 crossref_primary_10_3390_biomedicines11123208 crossref_primary_10_4065_mcp_2011_0128 crossref_primary_10_1016_j_lpm_2007_01_001 crossref_primary_10_1016_j_diabres_2009_01_016 crossref_primary_10_1185_03007990903073159 crossref_primary_10_1253_circj_CJ_23_0285 crossref_primary_10_3904_kjm_2014_87_1_19 crossref_primary_10_2146_ajhp060397 crossref_primary_10_1111_dme_12770 crossref_primary_10_1111_j_1755_5922_2012_00315_x crossref_primary_10_1210_js_2018_00079 crossref_primary_10_5812_semj_117171 crossref_primary_10_1517_13543784_2013_822485 crossref_primary_10_1002_wsbm_137 crossref_primary_10_1185_03007995_2010_503429 crossref_primary_10_1016_j_semnephrol_2018_01_003 crossref_primary_10_1016_j_arteri_2010_06_001 crossref_primary_10_1056_NEJMoa1206797 crossref_primary_10_1177_1474651406006001S0101 crossref_primary_10_1093_ndt_gfl212 crossref_primary_10_2337_dc16_1787 crossref_primary_10_1161_CIRCRESAHA_109_208355 crossref_primary_10_1016_j_atherosclerosis_2015_03_031 crossref_primary_10_2515_therapie_2007051 crossref_primary_10_2169_naika_102_902 crossref_primary_10_1007_s11886_008_0045_x crossref_primary_10_1161_CIRCULATIONAHA_105_620450 crossref_primary_10_5551_jat_48918 crossref_primary_10_2337_ds18_0009 crossref_primary_10_1097_FJC_0000000000000036 crossref_primary_10_1159_000443972 crossref_primary_10_1177_2042018813517522 crossref_primary_10_1016_j_amjcard_2009_07_052 crossref_primary_10_1016_j_curtheres_2006_10_002 crossref_primary_10_1093_ndt_gfq535 crossref_primary_10_1097_MOL_0b013e3283404ff1 crossref_primary_10_2174_1874192400903010057 crossref_primary_10_1016_j_endonu_2011_03_005 crossref_primary_10_1016_j_thromres_2007_10_014 crossref_primary_10_1016_j_clineuro_2008_04_010 crossref_primary_10_1152_physrev_00045_2011 crossref_primary_10_1586_erc_11_4 crossref_primary_10_1016_j_diabres_2011_07_028 crossref_primary_10_3390_ijms25020804 crossref_primary_10_1007_s00439_022_02434_z crossref_primary_10_2337_dc07_zb02 crossref_primary_10_2337_dc07_zb03 crossref_primary_10_1007_s00270_006_0183_8 crossref_primary_10_2337_dc07_zb08 crossref_primary_10_1016_j_atherosclerosis_2025_119146 crossref_primary_10_1016_j_jacc_2006_09_046 crossref_primary_10_1016_j_tcm_2022_11_003 crossref_primary_10_1002_cpt_1436 crossref_primary_10_1111_j_1476_5381_2012_02081_x crossref_primary_10_1111_j_1742_1241_2007_01412_x crossref_primary_10_1253_circj_CJ_20_0865 crossref_primary_10_1111_j_1463_1326_2008_00912_x crossref_primary_10_1016_j_amjcard_2007_02_001 crossref_primary_10_1016_j_atherosclerosis_2014_08_048 crossref_primary_10_1074_jbc_M705831200 crossref_primary_10_1194_jlr_M700345_JLR200 crossref_primary_10_1592_phco_27_5_715 crossref_primary_10_1016_j_ihj_2024_01_010 crossref_primary_10_1016_j_tcm_2017_04_002 crossref_primary_10_1111_j_1444_0938_2012_00725_x crossref_primary_10_2337_dc21_2511 crossref_primary_10_1093_eurheartj_ehp556 crossref_primary_10_1111_jphp_13267 crossref_primary_10_1111_j_1742_1241_2010_02547_x crossref_primary_10_1586_erc_10_108 crossref_primary_10_1038_srep42477 crossref_primary_10_1016_S1957_2557_09_73304_8 crossref_primary_10_1161_JAHA_112_002923 crossref_primary_10_1016_j_amjcard_2010_07_041 crossref_primary_10_1016_j_atherosclerosis_2009_08_026 crossref_primary_10_2337_dc19_S010 crossref_primary_10_1053_j_ajkd_2014_11_033 crossref_primary_10_1111_jgs_12035 crossref_primary_10_1016_j_jacl_2013_04_001 crossref_primary_10_1586_eop_09_5 crossref_primary_10_1155_2020_6865190 crossref_primary_10_1007_s13410_015_0338_8 crossref_primary_10_1007_s40292_017_0211_6 crossref_primary_10_4103_jigims_jigims_6_20 crossref_primary_10_1002_cmdc_200700165 crossref_primary_10_1111_j_1742_1241_2007_01425_x crossref_primary_10_3109_07853890_2011_588246 crossref_primary_10_1007_s11883_010_0150_3 crossref_primary_10_3390_biomedicines13010212 crossref_primary_10_2217_dmt_14_19 crossref_primary_10_2165_11539550_000000000_00000 crossref_primary_10_1161_CIR_0000000000000230 crossref_primary_10_1177_0960327121991901 crossref_primary_10_1016_j_nurpra_2013_08_017 crossref_primary_10_1186_s41100_016_0069_4 crossref_primary_10_1210_jc_2012_2267 crossref_primary_10_1016_j_amjcard_2008_03_076 crossref_primary_10_5694_j_1326_5377_2009_tb02684_x crossref_primary_10_1007_s11745_008_3187_0 crossref_primary_10_1177_14746514070070030801 crossref_primary_10_1111_j_1742_1241_2010_02382_x crossref_primary_10_1007_s11745_014_3965_9 crossref_primary_10_1007_s40119_020_00170_x crossref_primary_10_1097_MOL_0b013e3282f0ee11 crossref_primary_10_3390_molecules26196012 crossref_primary_10_1016_j_clinthera_2007_05_012 crossref_primary_10_1016_j_jclinepi_2006_10_020 crossref_primary_10_5124_jkma_2015_58_8_745 crossref_primary_10_1007_s11886_012_0309_3 crossref_primary_10_1161_STROKEAHA_122_036889 crossref_primary_10_1007_s00592_019_01319_4 crossref_primary_10_1016_j_amjmed_2015_06_027 crossref_primary_10_1016_j_clnu_2021_09_004 crossref_primary_10_3390_molecules24142545 crossref_primary_10_1002_sim_7975 crossref_primary_10_1080_09286586_2016_1193618 crossref_primary_10_36290_far_2016_018 crossref_primary_10_1080_10790268_2019_1581694 crossref_primary_10_1016_j_amjcard_2010_05_005 crossref_primary_10_1177_1479164114525548 crossref_primary_10_1016_j_atherosclerosissup_2006_05_003 crossref_primary_10_1128_AAC_05076_11 crossref_primary_10_1371_journal_pone_0241195 crossref_primary_10_1007_s11886_015_0589_5 crossref_primary_10_1016_S1634_7072_16_81776_6 crossref_primary_10_1016_j_exer_2021_108617 crossref_primary_10_1373_clinchem_2008_117754 crossref_primary_10_1016_S1567_5688_15_30001_5 crossref_primary_10_1016_j_ophtha_2016_05_042 crossref_primary_10_1007_s00125_023_06052_w crossref_primary_10_1016_j_jacc_2020_09_610 crossref_primary_10_1016_j_ebiom_2017_07_008 crossref_primary_10_1016_S0084_3873_08_79322_2 crossref_primary_10_1185_03007995_2010_490468 crossref_primary_10_1194_jlr_M034132 crossref_primary_10_1038_nrendo_2010_89 crossref_primary_10_1097_FPC_0000000000000219 crossref_primary_10_1016_j_diabres_2007_09_011 crossref_primary_10_1016_j_cardfail_2007_07_007 crossref_primary_10_1111_j_1463_1326_2006_00668_x crossref_primary_10_1016_j_atherosclerosis_2018_12_024 crossref_primary_10_1016_j_ijcard_2012_03_127 crossref_primary_10_1007_s40292_024_00682_w crossref_primary_10_1007_s13340_018_0365_z crossref_primary_10_1080_14737167_2018_1407246 crossref_primary_10_1016_j_jcin_2009_04_004 crossref_primary_10_1186_s12872_020_01567_1 crossref_primary_10_1161_CIRCULATIONAHA_107_746610 crossref_primary_10_1253_circj_CJ_23_0694 crossref_primary_10_5551_jat_35626 crossref_primary_10_1007_s00125_021_05532_1 crossref_primary_10_1007_s11883_022_01012_y crossref_primary_10_1177_1753944708090924 crossref_primary_10_1097_MPA_0000000000001152 crossref_primary_10_1176_appi_ps_201100475 crossref_primary_10_1016_j_yexmp_2021_104723 crossref_primary_10_1016_j_pharmthera_2014_02_001 crossref_primary_10_1007_s40265_016_0609_9 crossref_primary_10_2337_dc07_0015 crossref_primary_10_1016_j_bbalip_2011_10_003 crossref_primary_10_1016_j_metabol_2007_05_003 crossref_primary_10_1248_bpb_b13_00418 crossref_primary_10_1038_ncpendmet1066 crossref_primary_10_1007_s12325_012_0017_9 crossref_primary_10_1016_j_biopha_2018_07_157 crossref_primary_10_1016_j_pharmthera_2011_04_001 crossref_primary_10_1016_j_repce_2019_11_005 crossref_primary_10_1007_s40265_020_01265_4 crossref_primary_10_1253_circj_CJ_10_0934 crossref_primary_10_1007_s40265_025_02158_0 crossref_primary_10_1177_1538574416628655 crossref_primary_10_3390_jcm10040886 crossref_primary_10_1016_S0140_6736_10_60758_1 crossref_primary_10_1016_j_jacl_2007_01_004 crossref_primary_10_1186_s13098_021_00626_7 crossref_primary_10_1007_s42000_018_0014_8 crossref_primary_10_1111_bcpt_13369 crossref_primary_10_1016_j_amjcard_2008_10_002 crossref_primary_10_1080_17425255_2020_1822324 crossref_primary_10_1177_1753944707082662 crossref_primary_10_3109_13697137_2011_590618 crossref_primary_10_1016_j_clinthera_2015_07_021 crossref_primary_10_1016_j_diabet_2014_11_006 crossref_primary_10_1007_s00125_007_0919_2 crossref_primary_10_4093_dmj_2011_35_4_327 crossref_primary_10_1001_jamaophthalmol_2018_6399 crossref_primary_10_2337_dc21_1288 crossref_primary_10_1007_s11154_010_9132_6 crossref_primary_10_1007_s11745_011_3538_0 crossref_primary_10_1007_s00125_008_0975_2 crossref_primary_10_1016_j_beem_2013_12_001 crossref_primary_10_1038_nrendo_2010_50 crossref_primary_10_1038_s41433_020_0961_6 crossref_primary_10_1080_00325481_2018_1436843 crossref_primary_10_2217_thy_09_32 crossref_primary_10_1177_0003319709331392 crossref_primary_10_12968_indn_2006_1_10_74325 crossref_primary_10_1016_j_jtcvs_2023_05_028 crossref_primary_10_1157_13099714 crossref_primary_10_2337_db22_0654 crossref_primary_10_1007_s12325_010_0033_6 crossref_primary_10_1016_j_addr_2020_10_006 crossref_primary_10_3390_nu13010241 crossref_primary_10_1016_j_eprac_2022_08_002 crossref_primary_10_1038_ki_2010_530 crossref_primary_10_4061_2011_175381 crossref_primary_10_1016_S0140_6736_10_61481_X crossref_primary_10_1159_000445286 crossref_primary_10_1097_gme_0b013e31802e8508 crossref_primary_10_2217_fca_2015_0011 crossref_primary_10_2337_dc11_1307 crossref_primary_10_1161_ATVBAHA_118_307026 crossref_primary_10_1016_S1155_1941_11_51209_0 crossref_primary_10_1016_S1957_2557_14_70868_5 crossref_primary_10_1007_s11883_014_0437_x crossref_primary_10_1038_srep07706 crossref_primary_10_1136_jcp_2008_060913 crossref_primary_10_1177_147916410600300105 crossref_primary_10_1177_147916410600300104 crossref_primary_10_1177_147916410600300103 crossref_primary_10_1161_ATVBAHA_118_311117 crossref_primary_10_1097_01_hjr_0000368196_17109_5e crossref_primary_10_1007_s11883_024_01246_y crossref_primary_10_1111_j_1755_5922_2011_00300_x crossref_primary_10_1155_2015_271983 crossref_primary_10_1210_clinem_dgad656 crossref_primary_10_3390_nu16244318 crossref_primary_10_1517_14656566_2011_585462 crossref_primary_10_2337_diaclin_24_4_189 crossref_primary_10_1002_hep_23049 crossref_primary_10_1097_FJC_0b013e31829dd857 crossref_primary_10_1093_ehjcvp_pvad044 crossref_primary_10_1007_s11883_011_0162_7 crossref_primary_10_1016_j_hlc_2019_03_019 crossref_primary_10_1161_ATVBAHA_123_318977 crossref_primary_10_1177_1074248414537706 crossref_primary_10_1016_j_ejphar_2015_03_089 crossref_primary_10_1002_clc_20405 crossref_primary_10_1016_j_jacl_2018_03_077 crossref_primary_10_1097_FJC_0b013e3181bad05d crossref_primary_10_1161_STROKEAHA_113_004229 crossref_primary_10_1016_j_yend_2012_05_053 crossref_primary_10_1016_j_jhep_2023_07_004 crossref_primary_10_1016_j_cct_2020_106170 crossref_primary_10_12968_npre_2013_11_12_609 crossref_primary_10_1111_j_1365_2796_2008_02062_x crossref_primary_10_1007_s11892_017_0942_8 crossref_primary_10_1177_1753944708096281 crossref_primary_10_1001_jamacardio_2016_4828 crossref_primary_10_1016_S1885_5857_10_70065_7 crossref_primary_10_1007_s00125_006_0551_6 crossref_primary_10_1007_s11892_019_1136_3 crossref_primary_10_1016_j_jacc_2008_10_024 crossref_primary_10_1038_s41569_022_00676_y crossref_primary_10_1155_2021_3654660 crossref_primary_10_4070_kcj_2016_46_3_324 crossref_primary_10_1016_j_cjca_2016_01_003 crossref_primary_10_1097_MOL_0000000000000248 crossref_primary_10_1097_01_hjr_0000277985_25720_16 crossref_primary_10_1161_HYPERTENSIONAHA_107_086926 crossref_primary_10_1586_14779072_2014_888312 crossref_primary_10_1016_j_clinthera_2013_02_004 crossref_primary_10_1016_j_beem_2022_101659 crossref_primary_10_1586_erc_11_61 crossref_primary_10_1007_s11883_009_0006_x crossref_primary_10_1161_ATVBAHA_124_321165 crossref_primary_10_1093_eurheartj_ehs227 crossref_primary_10_1097_MED_0b013e3280d5f7e9 crossref_primary_10_2217_17460875_2_3_313 crossref_primary_10_4065_83_3_333 crossref_primary_10_1136_jcp_2022_208513 crossref_primary_10_1155_2007_39654 crossref_primary_10_2337_dc17_S012 crossref_primary_10_1016_S0084_3873_08_70201_3 crossref_primary_10_2217_17460816_1_2_259 crossref_primary_10_1016_S1575_0922_09_73517_X crossref_primary_10_1186_s13063_020_04291_5 crossref_primary_10_56095_eaj_v2i3_55 crossref_primary_10_3390_ijms19124058 crossref_primary_10_1161_CIR_0000000000000182 crossref_primary_10_1016_j_jacc_2007_08_055 crossref_primary_10_1002_clc_20412 crossref_primary_10_12997_jla_2013_2_1_19 crossref_primary_10_1016_j_ijge_2012_09_001 crossref_primary_10_1586_14779072_4_2_161 crossref_primary_10_1161_CIRCRESAHA_114_300935 crossref_primary_10_1097_01_mol_0000226115_97436_c0 crossref_primary_10_1007_s11936_012_0167_8 crossref_primary_10_1007_s11886_014_0506_3 crossref_primary_10_1586_ecp_10_51 crossref_primary_10_1161_CIRCULATIONAHA_104_475673 crossref_primary_10_2217_clp_13_16 crossref_primary_10_1016_j_medcli_2009_10_010 crossref_primary_10_2337_dc12_0306 crossref_primary_10_2165_11319800_000000000_00000 crossref_primary_10_1007_s11883_020_00897_x crossref_primary_10_3390_medicina56040177 crossref_primary_10_1038_s41598_019_53753_7 crossref_primary_10_1097_MED_0000000000000802 crossref_primary_10_1093_eurheartj_eht571 crossref_primary_10_36290_med_2017_055 crossref_primary_10_1007_s00228_011_1063_y crossref_primary_10_1016_j_clinthera_2009_04_015 crossref_primary_10_1097_MOL_0000000000000612 crossref_primary_10_2217_17460875_1_2_131 crossref_primary_10_1371_journal_pone_0137733 crossref_primary_10_5551_jat_RV16003 crossref_primary_10_1007_s40256_019_00363_3 crossref_primary_10_1155_2017_1069718 crossref_primary_10_1157_13084642 crossref_primary_10_1507_endocrj_EJ20_0808 crossref_primary_10_1111_j_1463_1326_2009_01159_x crossref_primary_10_1097_MJT_0b013e318293b0f9 crossref_primary_10_1038_sj_jhh_1002126 crossref_primary_10_1007_s40664_013_0003_3 crossref_primary_10_4070_kcj_2007_37_12_599 crossref_primary_10_1016_S0140_6736_10_60656_3 crossref_primary_10_1016_j_amjcard_2015_08_039 crossref_primary_10_1093_ehjcvp_pvad074 crossref_primary_10_2217_thy_11_5 crossref_primary_10_1038_ki_2011_36 crossref_primary_10_1186_s12933_024_02422_9 crossref_primary_10_1016_j_ancard_2008_02_004 crossref_primary_10_1540_jsmr_46_125 crossref_primary_10_1016_j_recesp_2021_10_016 crossref_primary_10_1097_MJT_0b013e31820159aa crossref_primary_10_1194_jlr_M020404 crossref_primary_10_2337_dc11_0840 crossref_primary_10_1124_pr_115_012203 crossref_primary_10_1177_1474651406006002S0401 crossref_primary_10_1016_j_metabol_2011_05_004 crossref_primary_10_1111_j_1742_1241_2010_02378_x crossref_primary_10_4158_EP_17_S2_1 crossref_primary_10_1007_s11883_022_01052_4 crossref_primary_10_1007_s11883_023_01142_x crossref_primary_10_1016_j_atherosclerosis_2011_06_024 crossref_primary_10_1093_eurheartj_sux029 crossref_primary_10_1016_j_atherosclerosis_2011_06_028 crossref_primary_10_1016_j_jacc_2015_06_1356 crossref_primary_10_1111_dom_15106 crossref_primary_10_1186_s12882_016_0414_4 crossref_primary_10_1517_14728214_13_2_363 crossref_primary_10_1155_2015_296417 crossref_primary_10_1371_journal_pone_0094585 crossref_primary_10_1016_S0716_8640_12_70368_1 crossref_primary_10_1515_CCLM_2008_016 crossref_primary_10_2337_dc10_S011 crossref_primary_10_1007_BF03256580 crossref_primary_10_1016_j_atherosclerosis_2011_06_012 crossref_primary_10_1093_cid_civ385 crossref_primary_10_3389_fmed_2015_00052 crossref_primary_10_1016_j_atherosclerosis_2023_117187 crossref_primary_10_1093_eurheartj_eht108 crossref_primary_10_1016_j_atherosclerosis_2015_10_019 crossref_primary_10_15829_1560_4071_2023_5688 crossref_primary_10_7759_cureus_22852 crossref_primary_10_1186_s41043_023_00478_z crossref_primary_10_1097_01_mjt_0000212890_82339_8d crossref_primary_10_1517_14656566_8_17_3009 crossref_primary_10_1016_j_atherosclerosis_2012_01_029 crossref_primary_10_3390_ph15101278 crossref_primary_10_1517_14728214_2014_976553 crossref_primary_10_1093_eurheartj_sum041 crossref_primary_10_1093_ehjcvp_pvad090 crossref_primary_10_3400_avd_ra_17_00109 crossref_primary_10_1161_JAHA_119_014890 crossref_primary_10_1111_j_1753_0407_2010_00108_x crossref_primary_10_1002_biof_1202 crossref_primary_10_1007_s10557_012_6395_z crossref_primary_10_1111_j_1464_5491_2011_03347_x crossref_primary_10_1016_j_atherosclerosissup_2006_01_006 crossref_primary_10_1586_erc_09_125 crossref_primary_10_1016_j_atherosclerosis_2011_08_015 crossref_primary_10_1111_ijcp_12126 crossref_primary_10_1016_j_atherosclerosis_2010_11_022 crossref_primary_10_3390_biology11070997 crossref_primary_10_2217_17460875_2_2_127 crossref_primary_10_2337_dc17_1589 crossref_primary_10_4070_kcj_2018_0343 crossref_primary_10_2337_dc07_1391 crossref_primary_10_1016_j_jval_2019_08_007 crossref_primary_10_2337_diacare_29_04_06_dc05_1967 crossref_primary_10_1016_j_jacl_2009_02_007 crossref_primary_10_5551_jat_No786 crossref_primary_10_4236_fns_2012_32037 crossref_primary_10_1016_j_acvd_2008_08_006 crossref_primary_10_1097_MOL_0000000000000657 crossref_primary_10_1053_j_ajkd_2008_01_014 crossref_primary_10_5551_jat_5868 crossref_primary_10_1016_j_jacc_2024_05_028 crossref_primary_10_1016_j_pcad_2016_07_009 crossref_primary_10_1186_s12916_015_0503_4 crossref_primary_10_3390_diseases6020044 crossref_primary_10_1007_s11886_013_0391_1 crossref_primary_10_1097_MED_0b013e3282c3a898 crossref_primary_10_1080_13813450802181013 crossref_primary_10_1097_QAD_0b013e328341dd68 crossref_primary_10_33678_cor_2009_032 crossref_primary_10_1007_s11892_010_0124_4 crossref_primary_10_2217_clp_10_1 crossref_primary_10_1016_j_metabol_2013_08_017 crossref_primary_10_1097_MOL_0000000000000640 crossref_primary_10_1016_j_bbrc_2017_11_145 crossref_primary_10_3390_diagnostics10050314 crossref_primary_10_1194_jlr_R082271 crossref_primary_10_1185_03007995_2011_620083 crossref_primary_10_1016_j_ajo_2012_03_013 crossref_primary_10_1590_S0004_27302007000200018 crossref_primary_10_1007_s11883_018_0721_2 crossref_primary_10_1160_TH13_01_0048 crossref_primary_10_1517_14728214_12_3_367 crossref_primary_10_1016_S1957_2557_10_70082_1 crossref_primary_10_1007_s11886_017_0818_1 crossref_primary_10_1016_j_ajpc_2023_100604 crossref_primary_10_1111_jch_14887 crossref_primary_10_1111_j_1463_1326_2010_01342_x crossref_primary_10_1177_14746514070070010201 crossref_primary_10_1590_S0004_27302007000200027 crossref_primary_10_1007_s12020_023_03401_y crossref_primary_10_3233_CH_201016 crossref_primary_10_56095_eaj_v1i2_14 crossref_primary_10_2337_db23_0811 crossref_primary_10_1016_j_bbamcr_2012_08_014 crossref_primary_10_1517_14728214_11_3_379 crossref_primary_10_1016_j_bbalip_2011_10_016 crossref_primary_10_1185_030079906X89865 crossref_primary_10_1007_s00125_010_1942_2 crossref_primary_10_14341_DM2014451_59 crossref_primary_10_1016_S0755_4982_06_74745_5 crossref_primary_10_1016_j_aca_2015_02_022 crossref_primary_10_1124_pr_119_017897 crossref_primary_10_1016_j_ecl_2014_08_005 crossref_primary_10_1080_13543784_2019_1582028 crossref_primary_10_1093_eurheartj_eht142 crossref_primary_10_3389_fendo_2024_1409653 crossref_primary_10_33678_cor_2009_029 crossref_primary_10_1016_j_tcm_2009_06_002 crossref_primary_10_1111_j_1463_1326_2009_01048_x crossref_primary_10_1016_j_atherosclerosis_2016_06_047 crossref_primary_10_3390_biomedicines11102696 crossref_primary_10_1161_JAHA_114_001098 crossref_primary_10_1093_qjmed_hcn066 crossref_primary_10_1111_eci_14121 crossref_primary_10_1038_kisup_2012_72 crossref_primary_10_1002_cpt_263 crossref_primary_10_1080_14656566_2018_1543403 crossref_primary_10_1111_j_1559_4564_2006_05910_x crossref_primary_10_1161_CIRCRESAHA_115_305826 crossref_primary_10_4140_TCP_n_2021_284 crossref_primary_10_1155_2013_387849 crossref_primary_10_1177_0272989X11409049 crossref_primary_10_1007_s11883_007_0013_8 crossref_primary_10_1038_kisup_2012_67 crossref_primary_10_1007_s10741_010_9208_0 crossref_primary_10_1038_kisup_2012_68 crossref_primary_10_3390_ijms21239251 crossref_primary_10_2337_dc05_2415 crossref_primary_10_1097_MEG_0b013e32835af154 crossref_primary_10_3177_jnsv_64_41 crossref_primary_10_1016_j_arteri_2017_11_001 crossref_primary_10_12997_jla_2023_12_1_23 crossref_primary_10_3390_jcm12237432 crossref_primary_10_3390_ph18020147 crossref_primary_10_1002_cpt_1163 crossref_primary_10_1111_imj_14291 crossref_primary_10_1111_j_1742_1241_2007_01509_x crossref_primary_10_1136_jmedgenet_2014_102438 crossref_primary_10_1155_2010_828531 crossref_primary_10_1002_cpt_1127 crossref_primary_10_1007_s11892_018_1117_y crossref_primary_10_1016_j_diabet_2017_04_003 crossref_primary_10_1097_MOL_0b013e3283063901 crossref_primary_10_36290_vnl_2017_069 crossref_primary_10_1007_s40265_015_0390_1 crossref_primary_10_1016_j_ahj_2012_06_023 crossref_primary_10_1016_j_amjcard_2006_11_010 crossref_primary_10_1016_j_amjcard_2006_11_014 crossref_primary_10_1016_j_amjcard_2006_11_016 crossref_primary_10_1007_s11883_006_0032_x crossref_primary_10_1016_j_amjcard_2006_11_017 crossref_primary_10_3390_jcm11236949 crossref_primary_10_1016_j_rceng_2014_06_001 crossref_primary_10_1007_s11883_006_0054_4 crossref_primary_10_1016_j_atherosclerosis_2018_09_035 crossref_primary_10_1210_clinem_dgab609 crossref_primary_10_1161_ATVBAHA_107_148817 crossref_primary_10_2217_clp_13_69 crossref_primary_10_4239_wjd_v8_i7_317 crossref_primary_10_1016_j_ijcard_2007_04_172 crossref_primary_10_1007_s00059_016_4499_0 crossref_primary_10_1007_s11883_014_0398_0 crossref_primary_10_14341_omet12714 crossref_primary_10_1016_j_atherosclerosis_2022_04_020 crossref_primary_10_14814_phy2_13186 crossref_primary_10_1016_j_ahj_2010_11_017 crossref_primary_10_1007_s11883_008_0060_9 crossref_primary_10_1080_14789450_2017_1388743 crossref_primary_10_1097_HJH_0b013e32835e8227 crossref_primary_10_1177_1753944710375820 crossref_primary_10_1194_jlr_RA119000258 crossref_primary_10_1007_s11883_008_0007_1 crossref_primary_10_1056_NEJMcp070061 crossref_primary_10_1097_MD_0000000000023427 crossref_primary_10_1016_j_ijcard_2016_06_234 crossref_primary_10_1157_13100276 crossref_primary_10_1097_01_mol_0000226129_48123_30 crossref_primary_10_1016_j_metabol_2009_04_009 crossref_primary_10_1007_s11789_006_0005_1 crossref_primary_10_1016_j_arteri_2017_04_003 crossref_primary_10_1111_dme_12448 crossref_primary_10_1097_HCO_0000000000000678 crossref_primary_10_1007_s11883_020_00860_w crossref_primary_10_1155_2023_6329819 crossref_primary_10_3390_jcm12113652 crossref_primary_10_1093_ndt_gfu372 crossref_primary_10_2217_cpr_13_83 crossref_primary_10_2337_diaspect_19_4_202 crossref_primary_10_5551_jat_4820 crossref_primary_10_1002_pdi_921 crossref_primary_10_1007_s10557_021_07273_0 crossref_primary_10_1097_MOL_0b013e32832dd832 crossref_primary_10_1016_j_ijcard_2016_09_075 crossref_primary_10_1155_2012_950693 crossref_primary_10_1007_s11892_008_0013_2 crossref_primary_10_1007_s40266_015_0240_6 crossref_primary_10_1016_j_jcjo_2011_12_025 crossref_primary_10_1016_j_jtcvs_2019_09_195 crossref_primary_10_2217_dmt_11_29 crossref_primary_10_2217_dmt_11_28 crossref_primary_10_1016_j_dsx_2015_02_008 crossref_primary_10_1007_s00059_010_3332_4 crossref_primary_10_1016_j_bmcl_2009_05_057 crossref_primary_10_1016_S0140_6736_09_60959_4 crossref_primary_10_1016_j_amjcard_2006_11_004 crossref_primary_10_1016_j_amjcard_2006_11_008 crossref_primary_10_1002_ccd_22983 crossref_primary_10_1016_j_jacl_2019_07_004 crossref_primary_10_1007_s10753_013_9728_6 crossref_primary_10_1016_j_phrs_2017_12_030 crossref_primary_10_1157_13116656 crossref_primary_10_1177_1479164112448876 crossref_primary_10_1016_j_amjcard_2011_05_047 crossref_primary_10_1016_j_fmc_2015_07_007 crossref_primary_10_1016_j_atherosclerosis_2011_05_018 crossref_primary_10_1016_j_numecd_2013_05_002 crossref_primary_10_2165_11207690_000000000_00000 crossref_primary_10_1177_154431670603000404 crossref_primary_10_1016_j_bmc_2014_09_022 crossref_primary_10_1016_j_ecl_2022_01_004 crossref_primary_10_5551_jat_3988 crossref_primary_10_1016_j_ijcard_2012_01_013 crossref_primary_10_1007_s12020_023_03357_z crossref_primary_10_4274_meandros_galenos_2022_68815 crossref_primary_10_1042_CS20120588 crossref_primary_10_1016_j_jcjd_2013_07_015 crossref_primary_10_1016_j_cjca_2016_07_510 crossref_primary_10_1007_s40256_023_00594_5 crossref_primary_10_2337_db16_0046 crossref_primary_10_1089_met_2006_4_299 crossref_primary_10_1016_j_ijcard_2012_01_008 crossref_primary_10_1007_s11883_006_0076_y crossref_primary_10_1097_IIO_0b013e31819fd5d7 crossref_primary_10_1016_j_ecl_2008_11_003 crossref_primary_10_1016_j_ecl_2008_11_005 crossref_primary_10_1161_CIRCOUTCOMES_111_000039 crossref_primary_10_1155_2014_823154 crossref_primary_10_1016_j_atherosclerosis_2011_12_042 crossref_primary_10_1007_s11892_016_0825_4 crossref_primary_10_1097_01_mol_0000226131_32876_0d crossref_primary_10_1016_j_jacc_2023_02_034 crossref_primary_10_1016_S0084_3741_08_79139_X crossref_primary_10_2165_00003495_200767010_00013 crossref_primary_10_1007_s11789_011_0031_5 crossref_primary_10_1177_2047487319871733 crossref_primary_10_1097_01_hjr_0000368195_09485_17 crossref_primary_10_1177_10742484231189597 crossref_primary_10_1186_s12944_021_01434_8 crossref_primary_10_1017_S0007114511004120 crossref_primary_10_1038_nrneph_2012_37 crossref_primary_10_1016_j_diabres_2025_112080 crossref_primary_10_1016_j_ahj_2007_01_008 crossref_primary_10_1002_pdi_955 crossref_primary_10_1016_S0084_3741_08_70036_2 crossref_primary_10_1016_j_ahj_2007_12_012 crossref_primary_10_1016_S2211_9477_12_70003_1 crossref_primary_10_1136_jcp_2006_042994 crossref_primary_10_1080_00325481_2017_1376570 crossref_primary_10_1007_s40273_013_0047_4 crossref_primary_10_2337_dc22_S010 crossref_primary_10_1111_j_1463_1326_2008_01012_x crossref_primary_10_1016_j_crvasa_2013_01_007 crossref_primary_10_1097_MOL_0b013e3282f1ed84 crossref_primary_10_5551_jat_E560 crossref_primary_10_1080_14779072_2020_1749596 crossref_primary_10_1007_s00011_022_01615_w crossref_primary_10_1038_nrcardio_2011_23 crossref_primary_10_33678_cor_2010_056 crossref_primary_10_1080_14656566_2019_1649394 crossref_primary_10_1371_journal_pone_0181359 crossref_primary_10_1016_j_jacl_2011_08_008 crossref_primary_10_1177_14791641211032547 crossref_primary_10_2165_00019053_200725090_00009 crossref_primary_10_1016_S0140_6736_14_61332_5 crossref_primary_10_1002_pdi_1177 crossref_primary_10_1161_STR_0b013e3182112d08 crossref_primary_10_1016_j_atherosclerosis_2006_11_035 crossref_primary_10_1093_ajcn_87_1_114 crossref_primary_10_1111_j_1755_5922_2009_00121_x crossref_primary_10_1211_jpp_61_05_0015 crossref_primary_10_2337_dc17_0968 crossref_primary_10_1038_tpj_2011_40 crossref_primary_10_1161_ATVBAHA_118_312028 crossref_primary_10_5551_jat_44412 crossref_primary_10_1016_j_pharmthera_2006_02_003 crossref_primary_10_1016_j_trre_2013_12_004 crossref_primary_10_1177_14746514070070040701 crossref_primary_10_1007_s11745_013_3841_z crossref_primary_10_1586_erc_10_4 crossref_primary_10_1016_j_trsl_2011_01_014 crossref_primary_10_1007_s11886_015_0609_5 crossref_primary_10_1111_jdi_14056 crossref_primary_10_1097_MNH_0000000000000628 crossref_primary_10_14336_AD_2022_1208 crossref_primary_10_1038_s41440_017_0008_y crossref_primary_10_1111_j_1464_5491_2010_03036_x crossref_primary_10_1016_j_jacc_2009_12_069 crossref_primary_10_1016_j_pharmthera_2010_01_008 crossref_primary_10_1016_j_clinthera_2013_06_013 crossref_primary_10_31083_RCM25399 crossref_primary_10_1016_j_ajo_2008_09_016 crossref_primary_10_3390_ijms21249436 crossref_primary_10_1002_dmrr_3631 crossref_primary_10_2337_db10_1795 crossref_primary_10_1097_HCO_0000000000001136 crossref_primary_10_1016_j_clinthera_2015_09_001 crossref_primary_10_1016_j_ddmod_2012_08_004 crossref_primary_10_1016_j_dsx_2022_102470 crossref_primary_10_36290_vnl_2023_060 crossref_primary_10_1016_j_jcjd_2013_07_062 crossref_primary_10_1016_S1575_0922_06_71123_8 crossref_primary_10_1016_j_pharmthera_2023_108544 crossref_primary_10_1016_S0140_6736_06_69594_9 crossref_primary_10_1097_MOL_0b013e32833c1e74 crossref_primary_10_1111_1753_0407_12931 crossref_primary_10_1016_j_artere_2019_12_001 crossref_primary_10_3132_dvdr_2006_025 crossref_primary_10_4070_kcj_2012_42_11_741 crossref_primary_10_1586_erc_12_92 crossref_primary_10_18705_1607_419X_2008_14_3_245_256 crossref_primary_10_1016_j_arteri_2019_12_003 crossref_primary_10_1177_1474651409103867 crossref_primary_10_3132_dvdr_2006_021 crossref_primary_10_3132_dvdr_2006_023 crossref_primary_10_1097_HCO_0b013e32830c6c37 crossref_primary_10_1089_met_2008_0079 crossref_primary_10_6064_2012_482423 crossref_primary_10_1016_j_atherosclerosis_2023_117313 crossref_primary_10_1517_13543784_2011_591785 crossref_primary_10_1007_s00592_021_01752_4 crossref_primary_10_1007_s11892_006_0055_2 crossref_primary_10_1016_j_mcna_2014_09_002 crossref_primary_10_1016_j_recesp_2011_09_014 crossref_primary_10_3132_dvdr_2006_011 crossref_primary_10_1038_s41598_025_92933_6 crossref_primary_10_1097_MED_0000000000000398 crossref_primary_10_1007_s40265_013_0072_9 crossref_primary_10_1097_WNR_0000000000001496 crossref_primary_10_1152_ajpendo_00230_2006 crossref_primary_10_3389_ebm_2024_10142 crossref_primary_10_2215_CJN_08160910 crossref_primary_10_1111_j_1749_6632_2010_05837_x crossref_primary_10_1258_jrsm_2010_100033 crossref_primary_10_1310_sci1403_46 crossref_primary_10_2337_db19_0973 crossref_primary_10_1016_j_amjmed_2011_08_025 crossref_primary_10_1177_1074248417724868 crossref_primary_10_1016_j_rccar_2020_07_005 crossref_primary_10_1016_j_atherosclerosis_2013_06_026 crossref_primary_10_3109_09286586_2014_949783 crossref_primary_10_1016_j_medcli_2010_03_014 crossref_primary_10_2174_0929867326666190201142321 crossref_primary_10_1016_j_bbalip_2015_12_001 crossref_primary_10_1586_egh_12_79 crossref_primary_10_1111_j_1463_1326_2007_00751_x crossref_primary_10_1002_anie_201505111 crossref_primary_10_1007_s11892_007_0014_6 crossref_primary_10_1016_j_plipres_2018_06_001 crossref_primary_10_1016_j_yend_2011_06_037 crossref_primary_10_1093_clinchem_hvaa296 crossref_primary_10_1185_03007995_2010_489341 crossref_primary_10_1155_2014_621975 crossref_primary_10_1016_S1262_3636_07_80054_1 crossref_primary_10_1007_s11892_007_0036_0 crossref_primary_10_1161_01_ATV_0000256469_06782_d5 crossref_primary_10_1177_1060028018765939 crossref_primary_10_7554_eLife_56573 crossref_primary_10_1345_aph_1K013 crossref_primary_10_5124_jkma_2016_59_5_366 crossref_primary_10_1007_s00125_015_3652_2 crossref_primary_10_1172_JCI88894 crossref_primary_10_4070_kcj_2016_46_3_275 crossref_primary_10_1016_j_coph_2021_04_002 crossref_primary_10_1016_S1131_3587_23_00012_2 crossref_primary_10_1177_0003319717744315 crossref_primary_10_4158_EP161445_RA crossref_primary_10_1111_imj_16455 crossref_primary_10_1097_CRD_0000000000000023 crossref_primary_10_1042_CS20120198 crossref_primary_10_1016_j_plipres_2018_12_002 crossref_primary_10_1007_s00125_012_2771_2 crossref_primary_10_1016_S1473_3099_07_70287_6 crossref_primary_10_1016_j_atherosclerosis_2015_09_003 crossref_primary_10_1016_j_pathol_2018_10_017 crossref_primary_10_1111_dme_12089 crossref_primary_10_1016_j_ejim_2013_07_005 crossref_primary_10_1258_ijsa_2008_008419 crossref_primary_10_1002_dmrr_694 crossref_primary_10_1007_s10620_016_4250_y crossref_primary_10_2217_pgs_2019_0140 crossref_primary_10_1002_dmrr_693 crossref_primary_10_1016_j_orcp_2011_03_012 crossref_primary_10_1002_cam4_4847 crossref_primary_10_1177_14746514080080010601 crossref_primary_10_1111_1755_5922_12148 crossref_primary_10_1177_1358863X11399328 crossref_primary_10_1016_j_addr_2021_04_007 crossref_primary_10_1016_j_rce_2014_06_001 crossref_primary_10_1016_j_diabet_2016_07_033 crossref_primary_10_1177_1074248410374041 crossref_primary_10_1177_1479164111430715 crossref_primary_10_1016_j_jacc_2018_10_072 crossref_primary_10_1093_eurheartj_ehaa1050 crossref_primary_10_1586_erc_12_56 crossref_primary_10_1016_j_tcm_2009_12_003 crossref_primary_10_1016_S0304_5412_12_70441_9 crossref_primary_10_1080_17446651_2020_1750949 crossref_primary_10_1016_j_atherosclerosis_2016_02_029 crossref_primary_10_1097_MJT_0000000000000116 crossref_primary_10_1186_s12933_016_0415_4 crossref_primary_10_1186_s40795_016_0065_7 crossref_primary_10_1007_s40355_012_0006_x crossref_primary_10_1007_s41745_022_00346_5 crossref_primary_10_1016_j_ecl_2013_09_001 crossref_primary_10_1016_j_repce_2019_03_010 crossref_primary_10_1167_iovs_18_24155 crossref_primary_10_1016_j_artere_2017_07_002 crossref_primary_10_1016_j_artere_2017_07_004 crossref_primary_10_1080_14779072_2016_1221341 crossref_primary_10_1016_j_semerg_2014_10_015 crossref_primary_10_1016_j_amjcard_2006_06_008 crossref_primary_10_1517_14656560903575654 crossref_primary_10_1161_01_RES_0000243583_39694_1f crossref_primary_10_1177_1474651412462042 crossref_primary_10_1042_CS20160671 crossref_primary_10_1111_jdi_12243 crossref_primary_10_2217_clp_09_37 crossref_primary_10_1093_eurheartj_suw009 crossref_primary_10_7554_eLife_80560 crossref_primary_10_1056_NEJMra1216063 crossref_primary_10_1016_j_ihj_2024_02_003 crossref_primary_10_5551_jat_E619 crossref_primary_10_1097_MOL_0b013e32821f603b crossref_primary_10_1016_j_ahj_2007_07_011 crossref_primary_10_1016_j_atherosclerosis_2011_07_109 crossref_primary_10_1139_cjpp_2014_0480 crossref_primary_10_1161_CIRCIMAGING_121_012615 crossref_primary_10_1016_S0140_6736_06_68500_0 crossref_primary_10_1007_s11883_011_0219_7 crossref_primary_10_1016_j_jfma_2012_12_011 crossref_primary_10_15829_1560_4071_2019_9_44_51 crossref_primary_10_3109_08820538_2015_1114869 crossref_primary_10_1080_14656566_2024_2408369 crossref_primary_10_1016_j_ahj_2013_05_013 crossref_primary_10_1007_s12170_019_0603_3 crossref_primary_10_1038_nrcardio_2013_117 crossref_primary_10_1186_1758_5996_6_30 crossref_primary_10_5888_pcd14_160504 crossref_primary_10_1056_NEJMc1009236 crossref_primary_10_1007_s11886_017_0872_8 crossref_primary_10_3390_ijms23084305 crossref_primary_10_1097_MOL_0000000000000318 crossref_primary_10_1007_s11428_011_0814_9 crossref_primary_10_1016_S0140_6736_07_61607_9 crossref_primary_10_1586_14779072_6_10_1319 crossref_primary_10_3390_ijms24032345 crossref_primary_10_1016_j_ahj_2013_05_004 crossref_primary_10_1007_s10741_018_9682_3 crossref_primary_10_1177_1479164112441477 crossref_primary_10_1016_j_jacc_2008_04_055 crossref_primary_10_2165_00023210_200822020_00003 crossref_primary_10_1097_CRD_0000000000000468 crossref_primary_10_1016_j_arteri_2015_12_004 crossref_primary_10_1007_s11892_009_0043_4 crossref_primary_10_1016_j_arteri_2015_12_001 crossref_primary_10_1016_j_trre_2006_02_001 crossref_primary_10_1016_j_crvi_2007_02_016 crossref_primary_10_1016_j_bbamem_2014_10_016 crossref_primary_10_1517_14656561003774080 crossref_primary_10_1586_erc_12_13 crossref_primary_10_1155_2008_879523 crossref_primary_10_4065_83_8_932 crossref_primary_10_1016_j_artere_2018_02_001 crossref_primary_10_1038_nrcardio_2013_140 crossref_primary_10_1093_ije_dys065 crossref_primary_10_1016_j_atherosclerosis_2024_117556 crossref_primary_10_1111_j_1365_2702_2008_02507_x crossref_primary_10_4103_hm_hm_2_19 crossref_primary_10_1007_s12170_015_0452_7 crossref_primary_10_1097_MOL_0b013e3283189c2b crossref_primary_10_1210_er_2018_00184 crossref_primary_10_3389_fcvm_2020_00088 crossref_primary_10_1016_S1885_5857_06_60123_0 crossref_primary_10_1016_j_ijcard_2007_11_090 crossref_primary_10_1111_j_1365_2796_2007_01892_x crossref_primary_10_1016_j_atherosclerosis_2014_12_006 crossref_primary_10_1097_MOL_0b013e328341a5a8 crossref_primary_10_1586_14779072_5_3_491 crossref_primary_10_1111_j_1748_1716_2007_01752_x crossref_primary_10_1177_1474651412442409 crossref_primary_10_3390_jcm12010021 crossref_primary_10_1056_NEJMc080981 crossref_primary_10_1200_JCO_2011_39_7356 crossref_primary_10_1016_j_atherosclerosis_2015_07_038 crossref_primary_10_26599_1671_5411_2023_09_008 crossref_primary_10_1111_j_1742_1241_2011_02630_x crossref_primary_10_1016_j_jsxm_2016_07_004 crossref_primary_10_1016_S0140_6736_09_61040_0 crossref_primary_10_1517_14656566_2010_489553 crossref_primary_10_1016_j_survophthal_2023_01_007 crossref_primary_10_1016_j_diabet_2014_04_004 crossref_primary_10_14341_2072_0351_5498 crossref_primary_10_1210_clinem_dgab137 crossref_primary_10_1016_S1885_5857_08_60116_4 crossref_primary_10_1007_s13340_020_00439_5 crossref_primary_10_1111_cts_12412 crossref_primary_10_1007_s00592_021_01773_z crossref_primary_10_1586_erc_12_37 crossref_primary_10_1001_jamacardio_2018_2121 crossref_primary_10_1586_erc_12_39 crossref_primary_10_1007_s11883_017_0661_2 crossref_primary_10_3389_fphar_2023_1175021 crossref_primary_10_1161_CIRCULATIONAHA_119_041998 crossref_primary_10_1517_14656560902910092 crossref_primary_10_1016_j_biochi_2016_10_017 crossref_primary_10_1177_14746514060060040701 crossref_primary_10_1016_S0140_6736_08_60333_5 crossref_primary_10_1016_j_amjms_2017_06_011 crossref_primary_10_2217_fca_10_126 crossref_primary_10_2337_dc08_S012 crossref_primary_10_7793_jcoron_22_034 crossref_primary_10_5694_j_1326_5377_2006_tb00644_x crossref_primary_10_1007_s40265_018_0965_8 crossref_primary_10_1089_dia_2024_0548 crossref_primary_10_1371_journal_pone_0056193 crossref_primary_10_1007_s00059_014_4083_4 crossref_primary_10_1016_j_arr_2014_01_006 crossref_primary_10_1111_ijcp_12072 crossref_primary_10_1517_14656560903575639 crossref_primary_10_1016_j_trsl_2016_02_008 crossref_primary_10_4103_0975_3583_70898 crossref_primary_10_1016_j_jacl_2022_05_068 crossref_primary_10_1080_17446651_2023_2279533 crossref_primary_10_1111_eci_12342 crossref_primary_10_1016_j_amjcard_2008_09_068 crossref_primary_10_1016_j_ejvs_2006_07_005 crossref_primary_10_1093_qjmed_hcr027 crossref_primary_10_1097_01_mca_0000224406_60573_8e crossref_primary_10_1016_j_amjcard_2008_09_066 crossref_primary_10_1536_ihj_53_29 crossref_primary_10_1097_HCO_0b013e328353adc1 crossref_primary_10_4236_ijcm_2017_82008 crossref_primary_10_1016_j_atherosclerosis_2010_04_035 crossref_primary_10_1007_s11883_016_0609_y crossref_primary_10_2165_00024677_200605020_00003 crossref_primary_10_2217_17460875_3_3_237 crossref_primary_10_1016_j_atherosclerosis_2010_08_045 crossref_primary_10_1210_jc_2019_01338 crossref_primary_10_1016_j_jdiacomp_2021_108101 crossref_primary_10_1007_s11906_006_0028_5 crossref_primary_10_7759_cureus_63078 crossref_primary_10_1016_j_endinu_2024_09_001 crossref_primary_10_4239_wjd_v9_i1_1 crossref_primary_10_1007_s11883_013_0390_0 crossref_primary_10_1016_j_ophtha_2014_07_019 crossref_primary_10_1016_j_cytogfr_2014_07_005 crossref_primary_10_1253_circj_CJ_07_1081 crossref_primary_10_1016_j_amjcard_2008_09_074 crossref_primary_10_1016_j_amjcard_2008_09_072 crossref_primary_10_1016_j_amjcard_2008_09_073 crossref_primary_10_1016_j_amjcard_2008_09_071 crossref_primary_10_1371_journal_pone_0008580 crossref_primary_10_1016_j_amjcard_2016_10_029 crossref_primary_10_1007_s00125_014_3458_7 crossref_primary_10_1093_ehjopen_oeae010 crossref_primary_10_1016_S0214_9168_06_73703_2 crossref_primary_10_3143_geriatrics_48_253 crossref_primary_10_1080_14728214_2017_1269743 crossref_primary_10_1097_MOL_0b013e32831ac56c crossref_primary_10_1016_j_jamda_2008_07_006 crossref_primary_10_1080_08998280_2013_11928935 crossref_primary_10_1155_2013_686525 crossref_primary_10_1016_S1575_0922_08_76267_3 crossref_primary_10_2217_clp_10_84 crossref_primary_10_2337_dc07_0196 crossref_primary_10_1093_humupd_dms026 crossref_primary_10_1111_j_1440_1681_2010_05442_x crossref_primary_10_2337_dc11_1811 crossref_primary_10_1016_j_ahj_2013_03_019 crossref_primary_10_1007_s40267_016_0288_3 crossref_primary_10_1111_j_1463_1326_2007_00670_x crossref_primary_10_1111_j_1463_1326_2007_00715_x crossref_primary_10_1007_s11883_014_0429_x crossref_primary_10_24018_ejmed_2022_4_2_1220 crossref_primary_10_1111_eci_12325 crossref_primary_10_1097_01_hco_0000245739_47712_0a crossref_primary_10_1016_j_ajpc_2020_100086 crossref_primary_10_1093_ndt_gfn721 crossref_primary_10_4236_pp_2014_52019 crossref_primary_10_4137_JCM_S7863 crossref_primary_10_3109_08860221003759452 crossref_primary_10_1016_S1155_1941_08_48491_3 crossref_primary_10_1080_17460441_2023_2292039 crossref_primary_10_2217_clp_10_90 crossref_primary_10_1002_pdi_903 crossref_primary_10_1007_s11892_009_0078_6 crossref_primary_10_3390_ijms24097695 crossref_primary_10_2217_clp_10_74 crossref_primary_10_1016_j_diabres_2017_10_007 crossref_primary_10_1002_14651858_CD013318_pub2 crossref_primary_10_2174_011573403X272750240109052319 crossref_primary_10_20996_1819_6446_2019_15_2_282_288 crossref_primary_10_1038_s41575_020_00366_5 crossref_primary_10_1016_j_ajpc_2020_100096 crossref_primary_10_1097_MOL_0b013e328348a539 crossref_primary_10_2337_dc05_1146 crossref_primary_10_1080_14656566_2022_2054699 crossref_primary_10_1016_j_ando_2016_11_001 crossref_primary_10_1007_s11936_012_0220_7 crossref_primary_10_2217_clp_09_71 crossref_primary_10_2337_cd21_0019 crossref_primary_10_1080_14728222_2024_2362644 crossref_primary_10_1111_hepr_13571 crossref_primary_10_1016_j_atherosclerosis_2009_05_020 crossref_primary_10_2217_clp_10_65 crossref_primary_10_1586_14779072_7_1_85 crossref_primary_10_1007_s12170_010_0143_3 crossref_primary_10_1016_j_jdiacomp_2012_11_004 crossref_primary_10_1194_jlr_M700108_JLR200 crossref_primary_10_1517_14656566_7_13_1701 crossref_primary_10_2337_diaclin_26_1_3 crossref_primary_10_1253_circrep_CR_24_0081 crossref_primary_10_1016_j_amjcard_2008_07_010 crossref_primary_10_2146_ajhp070005 crossref_primary_10_1016_j_atherosclerosis_2009_03_008 crossref_primary_10_1161_CIRCULATIONAHA_113_005757 crossref_primary_10_3390_ijms20205055 crossref_primary_10_1016_S1131_3587_12_70041_9 crossref_primary_10_1016_S1957_2557_11_70003_7 crossref_primary_10_2217_clp_10_56 crossref_primary_10_1016_j_cytogfr_2019_06_002 crossref_primary_10_1038_sj_ki_5001834 crossref_primary_10_1093_ehjopen_oeae057 crossref_primary_10_2337_dc15_S011 crossref_primary_10_1161_ATVBAHA_113_302926 crossref_primary_10_3390_biomedicines9111602 crossref_primary_10_1080_14740338_2018_1394455 crossref_primary_10_15406_ghoa_2016_04_00112 crossref_primary_10_1016_j_diabet_2023_101428 crossref_primary_10_1016_j_diabres_2018_05_006 crossref_primary_10_1016_j_cger_2020_04_006 crossref_primary_10_1136_bmjopen_2018_021508 crossref_primary_10_2217_17460875_2_3_285 crossref_primary_10_1016_j_ihj_2023_11_002 crossref_primary_10_1016_j_ihj_2023_11_003 crossref_primary_10_1089_gtmb_2013_0340 crossref_primary_10_1002_cmdc_201100598 crossref_primary_10_1016_j_numecd_2023_02_011 crossref_primary_10_1056_NEJMoa073394 crossref_primary_10_1002_pst_535 crossref_primary_10_1016_j_amjcard_2012_04_003 crossref_primary_10_1038_s41598_021_98064_y crossref_primary_10_1016_j_jacc_2013_11_002 crossref_primary_10_1002_dmrr_3163 crossref_primary_10_5694_mja14_01248 crossref_primary_10_1007_s11936_008_0004_2 crossref_primary_10_1007_s11886_024_02055_0 crossref_primary_10_1161_01_STR_0000236632_58323_cd crossref_primary_10_1016_S1557_0843_09_80005_5 crossref_primary_10_1093_eurjpc_zwae090 crossref_primary_10_1016_j_artere_2023_07_002 crossref_primary_10_1111_dme_12492 crossref_primary_10_1016_j_thromres_2012_08_296 crossref_primary_10_1007_s11428_009_0444_7 crossref_primary_10_1016_j_amjcard_2008_09_092 crossref_primary_10_1161_CIRCULATIONAHA_106_684704 crossref_primary_10_1097_MOL_0b013e32800ff750 crossref_primary_10_1186_s12962_024_00591_8 crossref_primary_10_1186_s12933_024_02305_z crossref_primary_10_2217_17460875_1_3_275 crossref_primary_10_1056_NEJMoa2404143 crossref_primary_10_1210_clinem_dgaa674 crossref_primary_10_1056_NEJMoa2404147 crossref_primary_10_1177_14746514050050060601 crossref_primary_10_1016_j_beem_2007_09_004 crossref_primary_10_1007_s00508_023_02166_8 crossref_primary_10_1074_mcp_RA119_001765 |
| Cites_doi | 10.1001/jama.288.16.2015 10.1016/S0140-6736(05)67394-1 10.1016/S0140-6736(04)16895-5 10.1161/01.ATV.12.12.1496 10.1001/archinte.162.22.2597 10.2337/diacare.16.2.434 10.1159/000064083 10.1001/archinte.165.7.725 10.1016/S0140-6736(00)04209-4 10.2165/00003495-200262130-00013 10.2337/diacare.26.10.2713 10.1038/bjc.1977.1 10.1016/0021-9150(85)90003-6 10.1136/bmj.326.7388.528 10.1186/1475-2840-4-13 10.1007/BF00265546 10.1016/j.atherosclerosis.2003.10.003 10.1001/archinte.165.10.1154 10.2337/diacare.21.4.641 10.1038/bjc.1976.220 10.1016/S0140-6736(03)13636-7 10.1186/1475-2840-3-9 10.1007/s00125-003-1111-y 10.2337/diacare.15.7.820 10.1002/sim.4780122410 10.1016/0140-6736(92)92588-7 10.1056/NEJM198711123172001 10.1016/0735-1097(93)90758-S 10.1053/j.ajkd.2004.11.004 |
| ContentType | Journal Article |
| Copyright | 2005 Elsevier Ltd Copyright Lancet Ltd. Nov 26-Dec 2, 2005 |
| Copyright_xml | – notice: 2005 Elsevier Ltd – notice: Copyright Lancet Ltd. Nov 26-Dec 2, 2005 |
| CorporateAuthor | The FIELD study investigators FIELD study investigators |
| CorporateAuthor_xml | – name: The FIELD study investigators – name: FIELD study investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 |
| DOI | 10.1016/S0140-6736(05)67667-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Database Suite (ProQuest) Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database (ProQuest) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database (ProQuest) Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 1861 |
| ExternalDocumentID | 935480861 16310551 10_1016_S0140_6736_05_67667_2 S0140673605676672 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .55 .CO .FO .GJ 04C 0R~ 123 1B1 1P~ 1RT 1~5 29L 3EH 3O- 4.4 41~ 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 8WZ 9JM A6W AABNK AAEDT AAEDW AAEJM AAIKJ AAKAS AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABDBF ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ABWVN ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACRPL ACUHS ACVFH ADBBV ADCNI ADMUD ADNMO ADXHL ADZCM AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFFNX AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AGQPQ AHHHB AHMBA AHQJS AIGII AIIUN AITUG AJJEV AJRQY AJUYK AKBMS AKRWK AKVCP AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI ARTTT ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 D0S DU5 DWQXO EAP EAS EAU EAZ EBC EBD EBS EBU EFJIC EFKBS EGS EHN EIHBH EJD EMB EMK EMOBN ENC EO8 EO9 EP2 EP3 EPL EPS EPT ESX EVS EWM EX3 F5P FD8 FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IHE J1W J5H K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 MVM N9A NAPCQ O-L O9- OD. OO~ OVD OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO Q~Q R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ SV3 T5K TEORI TH9 TLN TWZ UAP UBE UHU UKHRP UQL UV1 WOQ WOW WUQ X7M XAX XDU XPP YYM YYQ Z5R ZGI ZMT ZXP ZY4 ~G0 3V. 88A AACTN AAYOK ABLVK ABTAH ABYKQ ACRZS AFKWA AHPSJ AJBFU AJOXV AMFUW M0L NHB RIG SDF XFK Y6R ZA5 AAYXX AFCTW AGRNS ALIPV CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c444t-6fef3bb523781fd08eb34af5c122d93df705885ac77b38bd8a41209b1707ef103 |
| IEDL.DBID | 8C1 |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Thu Sep 04 22:24:22 EDT 2025 Sat Aug 23 14:08:07 EDT 2025 Thu Apr 03 07:05:50 EDT 2025 Tue Jul 01 04:11:19 EDT 2025 Thu Apr 24 23:07:24 EDT 2025 Fri Feb 23 02:21:22 EST 2024 Tue Aug 26 20:21:39 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9500 |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c444t-6fef3bb523781fd08eb34af5c122d93df705885ac77b38bd8a41209b1707ef103 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 16310551 |
| PQID | 199036865 |
| PQPubID | 40246 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_68832285 proquest_journals_199036865 pubmed_primary_16310551 crossref_primary_10_1016_S0140_6736_05_67667_2 crossref_citationtrail_10_1016_S0140_6736_05_67667_2 elsevier_sciencedirect_doi_10_1016_S0140_6736_05_67667_2 elsevier_clinicalkey_doi_10_1016_S0140_6736_05_67667_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2005-11-26 |
| PublicationDateYYYYMMDD | 2005-11-26 |
| PublicationDate_xml | – month: 11 year: 2005 text: 2005-11-26 day: 26 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2005 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Assmann, Schulte (bib10) 1991; 22 Gami, Montori, Erwin, Khan, Smith (bib28) 2003; 326 (bib21) 2005; 4 (bib17) 2001; 357 Syvanne, Whittall, Turpeinen (bib30) 2004; 172 (bib27) 2005; 366 Heady, Morris, Oliver (bib33) 1992; 340 Peto, Pike, Armitage (bib23) 1976; 34 Rubins, Robins, Collins (bib14) 2002; 162 Collett (bib25) 1994 Keating, Ormrod (bib11) 2002; 62 Ansquer, Foucher, Rattier, Taskinen, Steiner (bib34) 2005; 45 bib35 Frick, Elo, Haapa (bib12) 1987; 317 (bib22) 2001; 285 Tenenbaum, Motro, Fisman, Tanne, Boyko, Behar (bib15) 2005; 165 Fontbonne, Eschwege, Cambien (bib9) 1989; 32 Signorini, Leung, Simes, Beller, Gebski, Callaghan (bib19) 1993; 12 (bib20) 2003; 361 Koskinen, Mänttäri, Manninen, Huttunen, Heinonen, Frick (bib13) 1992; 15 (bib31) 2002; 288 Elkeles, Diamond, Poulter (bib16) 1998; 21 Feingold, Grunfeld, Pang (bib6) 1992; 12 Taskinen (bib8) 2003; 46 Peto, Pike, Armitage (bib24) 1977; 35 Barrett-Connor, Orchard (bib1) 1985 Keech, Colquhoun, Best (bib4) 2003; 26 (bib18) 2004; 3 Laakso, Voutilainen, Sarlund (bib5) 1985; 56 Studer, Briel, Leimenstoll, Glass, Bucher (bib26) 2005; 165 Stamler, Vaccaro, Neaton, Westworth (bib2) 1993; 16 Hottelart, El Esper, Rose, Hachard, Fournier (bib32) 2002; 92 Zuanetti, Latini, Maggioni (bib3) 1993; 22 Colhoun, Betteridge, Durrington (bib29) 2004; 364 Wilson, Kannel, Anderson (bib7) 1985; 13 Fontbonne (10.1016/S0140-6736(05)67667-2_bib9) 1989; 32 (10.1016/S0140-6736(05)67667-2_bib22) 2001; 285 (10.1016/S0140-6736(05)67667-2_bib18) 2004; 3 Heady (10.1016/S0140-6736(05)67667-2_bib33) 1992; 340 Koskinen (10.1016/S0140-6736(05)67667-2_bib13) 1992; 15 (10.1016/S0140-6736(05)67667-2_bib31) 2002; 288 Peto (10.1016/S0140-6736(05)67667-2_bib24) 1977; 35 (10.1016/S0140-6736(05)67667-2_bib17) 2001; 357 Frick (10.1016/S0140-6736(05)67667-2_bib12) 1987; 317 Syvanne (10.1016/S0140-6736(05)67667-2_bib30) 2004; 172 Taskinen (10.1016/S0140-6736(05)67667-2_bib8) 2003; 46 Signorini (10.1016/S0140-6736(05)67667-2_bib19) 1993; 12 (10.1016/S0140-6736(05)67667-2_bib27) 2005; 366 Wilson (10.1016/S0140-6736(05)67667-2_bib7) 1985; 13 Zuanetti (10.1016/S0140-6736(05)67667-2_bib3) 1993; 22 Elkeles (10.1016/S0140-6736(05)67667-2_bib16) 1998; 21 Collett (10.1016/S0140-6736(05)67667-2_bib25) 1994 Peto (10.1016/S0140-6736(05)67667-2_bib23) 1976; 34 Rubins (10.1016/S0140-6736(05)67667-2_bib14) 2002; 162 (10.1016/S0140-6736(05)67667-2_bib21) 2005; 4 Colhoun (10.1016/S0140-6736(05)67667-2_bib29) 2004; 364 Assmann (10.1016/S0140-6736(05)67667-2_bib10) 1991; 22 Gami (10.1016/S0140-6736(05)67667-2_bib28) 2003; 326 Ansquer (10.1016/S0140-6736(05)67667-2_bib34) 2005; 45 Stamler (10.1016/S0140-6736(05)67667-2_bib2) 1993; 16 Barrett-Connor (10.1016/S0140-6736(05)67667-2_bib1) 1985 Studer (10.1016/S0140-6736(05)67667-2_bib26) 2005; 165 Feingold (10.1016/S0140-6736(05)67667-2_bib6) 1992; 12 (10.1016/S0140-6736(05)67667-2_bib20) 2003; 361 Laakso (10.1016/S0140-6736(05)67667-2_bib5) 1985; 56 Hottelart (10.1016/S0140-6736(05)67667-2_bib32) 2002; 92 Tenenbaum (10.1016/S0140-6736(05)67667-2_bib15) 2005; 165 Keating (10.1016/S0140-6736(05)67667-2_bib11) 2002; 62 Keech (10.1016/S0140-6736(05)67667-2_bib4) 2003; 26 16616552 - Lancet. 2006 Apr 8;367(9517):1141; author reply 1142-3. doi: 10.1016/S0140-6736(06)68499-7 16646609 - ACP J Club. 2006 May-Jun;144(3):65. Lancet. 2006 Oct 21;368(9545):1420 16310536 - Lancet. 2005 Nov 26;366(9500):1829-31. doi: 10.1016/S0140-6736(05)67668-4 17213107 - Evid Based Med. 2006 Jun;11(3):86. doi: 10.1136/ebm.11.3.86 16616551 - Lancet. 2006 Apr 8;367(9517):1141-2; author reply 1142-3. doi: 10.1016/S0140-6736(06)68500-0 17055933 - Lancet. 2006 Oct 21;368(9545):1415. doi: 10.1016/S0140-6736(06)69594-9 |
| References_xml | – volume: 162 start-page: 2597 year: 2002 end-page: 2604 ident: bib14 article-title: Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) publication-title: Arch Intern Med – volume: 12 start-page: 2343 year: 1993 ident: bib19 article-title: Dynamic balanced randomization for clinical trials publication-title: Stat Med – volume: 165 start-page: 725 year: 2005 end-page: 730 ident: bib26 article-title: Effect of different antilipidemic agents and diets on mortality: a systemic review publication-title: Arch Intern Med – volume: 34 start-page: 585 year: 1976 end-page: 612 ident: bib23 article-title: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design publication-title: Br J Cancer – volume: 12 start-page: 1496 year: 1992 end-page: 1502 ident: bib6 article-title: LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes publication-title: Arterioscler Thromb – volume: 364 start-page: 685 year: 2004 end-page: 696 ident: bib29 article-title: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial publication-title: Lancet – volume: 22 start-page: 1788 year: 1993 end-page: 1794 ident: bib3 article-title: Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study publication-title: J Am Coll Cardiol – volume: 340 start-page: 1405 year: 1992 end-page: 1406 ident: bib33 article-title: WHO clofibrate/cholesterol trial: clarifications publication-title: Lancet – volume: 16 start-page: 434 year: 1993 end-page: 444 ident: bib2 article-title: Diabetes and other risk factors and the 12-year cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial publication-title: Diabetes Care – volume: 285 start-page: 2487 year: 2001 end-page: 2497 ident: bib22 article-title: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults publication-title: JAMA – volume: 172 start-page: 267 year: 2004 end-page: 272 ident: bib30 article-title: Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis publication-title: Atherosclerosis – year: 1994 ident: bib25 publication-title: Modeling survival data in medical research – volume: 317 start-page: 1237 year: 1987 end-page: 1245 ident: bib12 article-title: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia—safety treatment, changes in risk factors, and incidence of coronary heart disease publication-title: N Engl J Med – volume: 15 start-page: 820 year: 1992 end-page: 825 ident: bib13 article-title: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study publication-title: Diabetes Care – volume: 366 start-page: 1267 year: 2005 end-page: 1278 ident: bib27 article-title: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins publication-title: Lancet – volume: 357 start-page: 905 year: 2001 end-page: 910 ident: bib17 article-title: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study publication-title: Lancet – volume: 56 start-page: 271 year: 1985 end-page: 281 ident: bib5 article-title: Serum lipids and lipoproteins in middle aged non-insulin dependent diabetics publication-title: Atherosclerosis – volume: 361 start-page: 2005 year: 2003 end-page: 2016 ident: bib20 article-title: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial publication-title: Lancet – volume: 45 start-page: 485 year: 2005 end-page: 493 ident: bib34 article-title: Fenofibrate reduces progression to microalbuminuria over 3 years in the placebo-controlled study in type 2 diabetes: results from Diabetes Atherosclerosis Intervention Study (DAIS) publication-title: Am J Kidney Dis – volume: 35 start-page: 1 year: 1977 end-page: 39 ident: bib24 article-title: Design and analysis of randomised clinical trials requiring prolonged observation of each patient, 2: analysis and examples publication-title: Br J Cancer – start-page: 41 year: 1985 ident: bib1 article-title: Diabetes and heart disease publication-title: National Diabetes Data Group. Diabetes data compiled 1984 – volume: 13 start-page: 1 year: 1985 end-page: 11 ident: bib7 article-title: Lipids, glucose intolerance and vascular disease: The Framingham Study publication-title: Monogr Atheroscler – volume: 165 start-page: 1154 year: 2005 end-page: 1160 ident: bib15 article-title: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome publication-title: Arch Intern Med – volume: 92 start-page: 536 year: 2002 end-page: 541 ident: bib32 article-title: Fenofibrate increases creatininemia by increasing metabolic production of creatinine publication-title: Nephron – volume: 3 start-page: 9 year: 2004 ident: bib18 article-title: The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study publication-title: Cardiovasc Diabetol – ident: bib35 – volume: 26 start-page: 2713 year: 2003 end-page: 2721 ident: bib4 article-title: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial publication-title: Diabetes Care – volume: 4 start-page: 13 year: 2005 ident: bib21 article-title: Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate publication-title: Cardiovasc Diabetol – volume: 46 start-page: 733 year: 2003 end-page: 749 ident: bib8 article-title: Diabetic dyslipidaemia: from basic research to clinical practice publication-title: Diabetologia – volume: 22 start-page: 51 year: 1991 end-page: 57 ident: bib10 article-title: Triglycerides and atherosclerosis; results from the Prospective Cardiovascular Munster Study publication-title: Arterioscler Rev – volume: 326 start-page: 528 year: 2003 end-page: 529 ident: bib28 article-title: Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes publication-title: BMJ – volume: 62 start-page: 1909 year: 2002 end-page: 1944 ident: bib11 article-title: Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia publication-title: Drugs – volume: 288 start-page: 2015 year: 2002 end-page: 2222 ident: bib31 article-title: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis publication-title: JAMA – volume: 32 start-page: 300 year: 1989 end-page: 304 ident: bib9 article-title: Hypertriglyceridemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes publication-title: Diabetologia – volume: 21 start-page: 641 year: 1998 end-page: 648 ident: bib16 article-title: Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate—the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study publication-title: Diabetes Care – volume: 288 start-page: 2015 year: 2002 ident: 10.1016/S0140-6736(05)67667-2_bib31 article-title: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis publication-title: JAMA doi: 10.1001/jama.288.16.2015 – volume: 285 start-page: 2487 year: 2001 ident: 10.1016/S0140-6736(05)67667-2_bib22 article-title: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults publication-title: JAMA – volume: 366 start-page: 1267 year: 2005 ident: 10.1016/S0140-6736(05)67667-2_bib27 article-title: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins publication-title: Lancet doi: 10.1016/S0140-6736(05)67394-1 – volume: 364 start-page: 685 year: 2004 ident: 10.1016/S0140-6736(05)67667-2_bib29 article-title: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(04)16895-5 – volume: 12 start-page: 1496 year: 1992 ident: 10.1016/S0140-6736(05)67667-2_bib6 article-title: LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes publication-title: Arterioscler Thromb doi: 10.1161/01.ATV.12.12.1496 – volume: 162 start-page: 2597 year: 2002 ident: 10.1016/S0140-6736(05)67667-2_bib14 article-title: Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) publication-title: Arch Intern Med doi: 10.1001/archinte.162.22.2597 – volume: 16 start-page: 434 year: 1993 ident: 10.1016/S0140-6736(05)67667-2_bib2 article-title: Diabetes and other risk factors and the 12-year cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial publication-title: Diabetes Care doi: 10.2337/diacare.16.2.434 – volume: 92 start-page: 536 year: 2002 ident: 10.1016/S0140-6736(05)67667-2_bib32 article-title: Fenofibrate increases creatininemia by increasing metabolic production of creatinine publication-title: Nephron doi: 10.1159/000064083 – start-page: 41 year: 1985 ident: 10.1016/S0140-6736(05)67667-2_bib1 article-title: Diabetes and heart disease – volume: 165 start-page: 725 year: 2005 ident: 10.1016/S0140-6736(05)67667-2_bib26 article-title: Effect of different antilipidemic agents and diets on mortality: a systemic review publication-title: Arch Intern Med doi: 10.1001/archinte.165.7.725 – volume: 357 start-page: 905 year: 2001 ident: 10.1016/S0140-6736(05)67667-2_bib17 article-title: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study publication-title: Lancet doi: 10.1016/S0140-6736(00)04209-4 – volume: 62 start-page: 1909 year: 2002 ident: 10.1016/S0140-6736(05)67667-2_bib11 article-title: Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia publication-title: Drugs doi: 10.2165/00003495-200262130-00013 – volume: 26 start-page: 2713 year: 2003 ident: 10.1016/S0140-6736(05)67667-2_bib4 article-title: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial publication-title: Diabetes Care doi: 10.2337/diacare.26.10.2713 – volume: 35 start-page: 1 year: 1977 ident: 10.1016/S0140-6736(05)67667-2_bib24 article-title: Design and analysis of randomised clinical trials requiring prolonged observation of each patient, 2: analysis and examples publication-title: Br J Cancer doi: 10.1038/bjc.1977.1 – volume: 56 start-page: 271 year: 1985 ident: 10.1016/S0140-6736(05)67667-2_bib5 article-title: Serum lipids and lipoproteins in middle aged non-insulin dependent diabetics publication-title: Atherosclerosis doi: 10.1016/0021-9150(85)90003-6 – volume: 326 start-page: 528 year: 2003 ident: 10.1016/S0140-6736(05)67667-2_bib28 article-title: Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes publication-title: BMJ doi: 10.1136/bmj.326.7388.528 – volume: 4 start-page: 13 year: 2005 ident: 10.1016/S0140-6736(05)67667-2_bib21 article-title: Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate publication-title: Cardiovasc Diabetol doi: 10.1186/1475-2840-4-13 – volume: 13 start-page: 1 year: 1985 ident: 10.1016/S0140-6736(05)67667-2_bib7 article-title: Lipids, glucose intolerance and vascular disease: The Framingham Study publication-title: Monogr Atheroscler – volume: 32 start-page: 300 year: 1989 ident: 10.1016/S0140-6736(05)67667-2_bib9 article-title: Hypertriglyceridemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes publication-title: Diabetologia doi: 10.1007/BF00265546 – volume: 172 start-page: 267 year: 2004 ident: 10.1016/S0140-6736(05)67667-2_bib30 article-title: Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2003.10.003 – volume: 165 start-page: 1154 year: 2005 ident: 10.1016/S0140-6736(05)67667-2_bib15 article-title: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome publication-title: Arch Intern Med doi: 10.1001/archinte.165.10.1154 – volume: 21 start-page: 641 year: 1998 ident: 10.1016/S0140-6736(05)67667-2_bib16 article-title: Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate—the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study publication-title: Diabetes Care doi: 10.2337/diacare.21.4.641 – volume: 34 start-page: 585 year: 1976 ident: 10.1016/S0140-6736(05)67667-2_bib23 article-title: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design publication-title: Br J Cancer doi: 10.1038/bjc.1976.220 – volume: 361 start-page: 2005 year: 2003 ident: 10.1016/S0140-6736(05)67667-2_bib20 article-title: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(03)13636-7 – volume: 3 start-page: 9 year: 2004 ident: 10.1016/S0140-6736(05)67667-2_bib18 article-title: The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study publication-title: Cardiovasc Diabetol doi: 10.1186/1475-2840-3-9 – volume: 46 start-page: 733 year: 2003 ident: 10.1016/S0140-6736(05)67667-2_bib8 article-title: Diabetic dyslipidaemia: from basic research to clinical practice publication-title: Diabetologia doi: 10.1007/s00125-003-1111-y – volume: 15 start-page: 820 year: 1992 ident: 10.1016/S0140-6736(05)67667-2_bib13 article-title: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study publication-title: Diabetes Care doi: 10.2337/diacare.15.7.820 – volume: 22 start-page: 51 year: 1991 ident: 10.1016/S0140-6736(05)67667-2_bib10 article-title: Triglycerides and atherosclerosis; results from the Prospective Cardiovascular Munster Study publication-title: Arterioscler Rev – volume: 12 start-page: 2343 year: 1993 ident: 10.1016/S0140-6736(05)67667-2_bib19 article-title: Dynamic balanced randomization for clinical trials publication-title: Stat Med doi: 10.1002/sim.4780122410 – volume: 340 start-page: 1405 year: 1992 ident: 10.1016/S0140-6736(05)67667-2_bib33 article-title: WHO clofibrate/cholesterol trial: clarifications publication-title: Lancet doi: 10.1016/0140-6736(92)92588-7 – volume: 317 start-page: 1237 year: 1987 ident: 10.1016/S0140-6736(05)67667-2_bib12 article-title: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia—safety treatment, changes in risk factors, and incidence of coronary heart disease publication-title: N Engl J Med doi: 10.1056/NEJM198711123172001 – volume: 22 start-page: 1788 year: 1993 ident: 10.1016/S0140-6736(05)67667-2_bib3 article-title: Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study publication-title: J Am Coll Cardiol doi: 10.1016/0735-1097(93)90758-S – year: 1994 ident: 10.1016/S0140-6736(05)67667-2_bib25 – volume: 45 start-page: 485 year: 2005 ident: 10.1016/S0140-6736(05)67667-2_bib34 article-title: Fenofibrate reduces progression to microalbuminuria over 3 years in the placebo-controlled study in type 2 diabetes: results from Diabetes Atherosclerosis Intervention Study (DAIS) publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2004.11.004 – reference: - Lancet. 2006 Oct 21;368(9545):1420 – reference: 16646609 - ACP J Club. 2006 May-Jun;144(3):65. – reference: 16310536 - Lancet. 2005 Nov 26;366(9500):1829-31. doi: 10.1016/S0140-6736(05)67668-4 – reference: 16616551 - Lancet. 2006 Apr 8;367(9517):1141-2; author reply 1142-3. doi: 10.1016/S0140-6736(06)68500-0 – reference: 17213107 - Evid Based Med. 2006 Jun;11(3):86. doi: 10.1136/ebm.11.3.86 – reference: 16616552 - Lancet. 2006 Apr 8;367(9517):1141; author reply 1142-3. doi: 10.1016/S0140-6736(06)68499-7 – reference: 17055933 - Lancet. 2006 Oct 21;368(9545):1415. doi: 10.1016/S0140-6736(06)69594-9 |
| SSID | ssj0004605 |
| Score | 2.4869733 |
| Snippet | Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1849 |
| SubjectTerms | Aged Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Cholesterol Cholesterol - blood Coronary Disease - mortality Coronary Disease - prevention & control Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Dietary fiber Double-Blind Method Dyslipidemias - complications Dyslipidemias - drug therapy Female Fenofibrate - adverse effects Fenofibrate - therapeutic use Health risk assessment Health risks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypolipidemic Agents - adverse effects Hypolipidemic Agents - therapeutic use Male Middle Aged Mortality Myocardial infarction Statins Therapy Triglycerides - blood |
| Title | Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673605676672 https://dx.doi.org/10.1016/S0140-6736(05)67667-2 https://www.ncbi.nlm.nih.gov/pubmed/16310551 https://www.proquest.com/docview/199036865 https://www.proquest.com/docview/68832285 |
| Volume | 366 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZoKyEuiHe3hWUOHNpDaPyI7eWCyrKr8mhVAUV7i-JHENKStGT3wI_hvzJOnFRILeWUKMlESmb8ecae-YaQF9pqzWUguhXMJsIjDhpqcLgXXFsjjaNt57njE3l0Jt4vskXMzWliWmWPiS1Qu9qGNfIDirDJpZbZ6_OLJDSNCpursYPGBtkKJaAh9tJTelVZZJvhflnAc_B5uLiXZvtSSYQLdt3UdJ3r2U5B83vkbvQd4bBT9n1yy1cPyO3juDv-kPzuqIgbqEtY1tW3JMAulL5CAzKBEgK6aqtfUFdg_0pEhZbIqYHvFUzUJIMusRzCKi2EVVpg0K_Swo_A4blaN7CHr4P5u9nHt9Cy1O6_Apz5XI2m4x3EJPglnratQR6Rs_nsy_Qoie0XEiuEWCWy9CU3BiNVpWnpUo1xtyjKzFLG3IS7UqWZ1llhlTJcG6cLEbRgqEqVL2nKH5PNqq78NgEmCs4wHGY-0NXrtODKZQw9IbSH1HkxIqL_87mN3OShRcYyvyIJLc3yVmE5G5GXg9h5R85xk4Ds1Zr3laeIlTlOHzcJ6kEwuiady_E_oru9_eQRH5p8sOYReT7cRe2E3Zqi8vW6yaUOYKvxiSed0V1-ouShrSnd-eebd8mdjmaWJkw-JZurn2v_DB2olRmTDbVQ43awjMnW4Yev01M8vpmdnH76AxHIFlA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJwEviP-UAbsHkLaHsMR2HBdpQsBataytEGzS3kwcO9OkkgzSCu3D8FH4bpwTJxPSxnjZW5TkLCV3_vl8vvsdIS9lJiUTjuiW0yzgFnFQRxqne8pkpoU2Ud15bjYX40P-8Sg-WiO_21oYl1bZYmIN1KbMXIx8J0LYZEKK-O3p98A1jXKHq20HjdR3VjC7NcOYr-vYt2c_cQdX7U72UN2vKB0NDz6MA99kIMg458tA5DZnWuN-LJFRbkKJu0ue5nEWUWoGzORJGEsZp1mSaCa1kSl35aY6SsLE5lHIcNwbZJ27-EmPrL8fzj99vqgws86xPy8h2vnS3dwK422RCAQsetnieJnzWy-Co7vkjvde4V1jbvfImi3uk5szfz7_gPxqyJArKHNYlMVx4IAfclugCWtHSgFNvdcZlAVkf6XCQk0lVcFJAYNkEEOT2g4uTgwuTgwU2jgxfHMsostVBVs4HIwmw-ke1Dy5228A115TovFaAz4Nf4GXdXOSh-TwWnTziPSKsrBPCFCeMoobcmodYb4MU5aYmKIvhhYZGsv7hLd_XmWeHd016VioC9LgwljVClO0T153YqcNPchVAqJVq2prXxGtFS5gVwnKTtA7R43T8z-iG639KI9QlermU59sdk9RO-68KC1suaqUkA7uJb7xuDG6808UzDVWjZ7-c-RNcmt8MJuq6WS-v0FuN6S3UUDFM9Jb_ljZ5-jOLfULP2mAfL3uefoHNKlVog |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKK1VcEP8sBToHkNpD2MR2bC9ShYDdVZe2qwqo1JuJYwdV2iaF7Ar1YXgg3opx4myF1FIuvUVJxlIy__bMN4S8VLlSTHigW07ziDu0gyYxqO4ZU7kRxibN5LmDqdg94h-P0-MV8rvrhfFllZ1NbAy1rXK_R95P0GwyoUTaL0JVxOFw_Pbse-QHSPmD1m6aRhamLNidBm0s9HjsufOfmM3VO5Mhsv4VpePRlw-7URg4EOWc83kkClcwYzA3kyopbKww0-RZkeYJpXbAbCHjVKk0y6U0TBmrMu5bT00iY-mKJGa47i2yJtHpYx649n40Pfx0WZNmU29_0U7U_7y8uRWn20IKNF70Kkd5VSDcOMTxXXInRLLwrhW9e2TFlffJ-kE4q39AfrXAyDVUBcyq8lvknQAUrkRxNh6gAtrer3OoSsj_KouFBlaqhpMSBnKQQlvmDn7PGPyeMVDo9ozh1COKzhc1bOFyMJ6M9ofQYOZuvwH0w7ZCQXYWQkn-DC-bQSUPydGN8OYRWS2r0j0hQHnGKCbn1HnwfBVnTNqUYlyG0hlbx3uEd39e5wEp3Q_smOlLSuLiVDcM07RHXi_JzlqokOsIRMdW3fXBouXW6MyuI1RLwhAotQHQ_5BudPKjg7Wq9VK3emRz-RS548-OstJVi1oL5U2_wjcet0J38YmC-SGrydN_rrxJ1lFf9f5kurdBbrf4t0lExTOyOv-xcM8xspubF0FngHy9aTX9A7m1WeY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+long-term+fenofibrate+therapy+on+cardiovascular+events+in+9795+people+with+type+2+diabetes+mellitus+%28the+FIELD+study%29%3A+randomised+controlled+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Keech%2C+A&rft.au=Simes%2C+R+J&rft.au=Barter%2C+P&rft.au=Best%2C+J&rft.date=2005-11-26&rft.pub=Elsevier+Limited&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=366&rft.issue=9500&rft.spage=1849&rft_id=info:doi/10.1016%2FS0140-6736%2805%2967667-2&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=935480861 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |